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1. GLOSSARY 
4CMenB, 4 Component protein-based meningococcal B vaccine 
Ab, Antibody 
Ag, Antigen 
B, Blank 
BSA, Bovine Serum Albumin 
Capt, Capture 
CI, Confidential Interval 
Det, Detection 
ELISA, Enzyme-Linked Immunosorbent Assay 
EU, ELISA unit 
fH, factor H 
fHbp, factor H binding protein 
GNA, genome-derived Neisseria Antigen 
hSBA, Serum Bactericidal Assay using Human Complement 
LD, Lysis Detergent 
MATS, Meningococcal Antigen Typing System 
MenB, serogroup B meningococcus 
MenNZB, serogroup B meningococcus from New Zealand (NZ98/254 strain) 
MFI, Median Fluorescence Intensity 
MFI-B, Median Fluorescence Intensity minus Blank signal 
MH, Mueller Hinton  
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NadA, Neisseria adesin A 
NHBA, Neisseria Heparin Binding Antigen 
NZ, New Zealand 
OD, Optical Density 
OMVs, Outer Membrane Vesicles 
OMVnz, Outer Membrane Vesicles from NZ98/254 strain 
pAb, polyclonal Antibody 
PBT, Positive Bactericidal Threshold 
PE, Phycoeritrin 
PI, Pre-Immune 
PNAS, Proceedings of the National Academy of Sciences of U.S.A. 
PorA, Porine A 
QC, Quality Control 
RP, Relative Potency 
rSBA, Serum Bactericidal Assay using Rabbit Complement 
ρ, Spearman’s coefficient (rho) 
Sub-var., Sub-variant 
UK, United Kingdom 
Var., Variant 
VR, Variable Region  
WHO, World Health Organization 
xMAP, Multi-Analyte Profiling by Luminex Technology 
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2. SUMMARY  
 
Bexsero
TM
 vaccine against Neisseria meningitidis serogroup B (MenB) strains has been 
approved in several countries.  It is composed by three sub-capsular antigens, selected by reverse 
vaccinology approach: factor H binding protein (fHbp) variant 1.1, Neisseria Heparin Binding 
Antigen (NHBA) peptide 2 and Neisseria adesin A (NadA) variant 3. Bexsero
TM
 vaccine 
includes also Outer Membrane Vescicles (OMVs) derived from the New Zealand strain 
NZ98/254, expressing PorA serosubtype P1.4. Evaluation of antigen expression by circulating 
N. meningitidis strains is a very critical step in order to predict the vaccine coverage and, a 
specific test has been set up for this purpose (Boccadifuoco et al., 2012).  
The Meningococcal Antigen Typing System (MATS) was designed to measure immunologic 
cross-reactivity and quantify antigen content of target MenB strains. MATS results from a 
combination of three sandwich Enzyme-Linked Immunosorbent Assay (ELISA) assays, one for 
each vaccine antigen, plus sequencing of Porin A (PorA) P1.4 (Serruto et al., 2012). The readout 
of single meningococcal strains is expressed as Relative Potency (RP) for fHbp, NHBA, and 
NadA. RPs are calculated comparing serial dilution curves of tested strains with those of 
reference strains by a variance-weighted regression method. In order to determine RPs cut-off 
values able to predict strain susceptibility by human Serum Bactericidal Assay (hSBA), MATS 
RPs have been related to hSBA titers of 13-months-old children pooled sera, immunized with 
Bexsero
TM
 at 2, 4, 6, and 12 months of age (Donnelly et. al., 2010). This correlation has defined 
a Positive Bactericidal Threshold (PBT) for each vaccine antigen above which the majority of 
strains are killed in hSBA.  
Although working, conventional ELISA makes immunogenicity evaluation of a multi-
component vaccine difficult, laborious, time-consuming and expensive, since only one 
immunogen per assay run can be tested. 
xMap Luminex Technology allows the development of multiplex immunoassays where, multiple 
antibody types can be determined simultaneously in one assay run.  
Taking the case of MATS-ELISA assay and Bexsero
TM
 vaccine as reference, this PhD project 
aim to: (i) develop a flexible multiplex and quantitative sandwich assay (on Luminex platform) 
allowing the simultaneous measurement of all vaccine antigens expressed by bacterial strains, in 
order to predict the coverage of Bexsero
TM
; (ii) qualify the multiplex assay performance 
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(repeatability, sensitivity, precision, intra/inter assay variability); (iii) evaluate comparability of 
the new assay with the currently accepted ones, taking also into account results of the Serum 
Bactericidal Assay (SBA), the only accepted reference test for functional antibodies directed to 
meningococcus. 
A 4-plex assay based on Luminex Technology able to simultaneously quantify fHbp, NadA and 
NHBA content of serogroup B menigococcal isolates was developed. The possibility to 
multiplex, allows measuring also the OMVs content and, consequently, eliminating PorA 
sequencing. This step shows the way forward to speculating on a possible role of other OMVs-
components (not only PorA-correlated) in the coverage of Bexsero
TM
.  
We tested a 28-strains panel on optimized Luminex 4-plex assay in order to investigate the 
correlation with MATS data. These 28 strains are a sub-set of a 57-strains panel selected in 2010 
by Donnelly et al. to correlate MATS results with hSBA titers.  
Statistical analysis showed that, Luminex 4-plex assay is close correlated with MATS assay in 
terms of Relative Potencies (RPs) and has RPs strain rank highly correlated for each antigen.  
After validation and further investigation, Luminex 4-plex assay could represent a promising test 
to obtain information about Bexsero
TM 
coverage in easy, fast, cheap and more reproducible way. 
Furthermore, due to the high flexibility of this technology it will be possible to increase the 
antigens panel (from 4 up to 100 microspheres in the single well) and detect other vaccine 
antigens expressed on bacterial strain to predict the coverage of a new generation multi-
component vaccine. 
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3. PhD PROJECT RATIONALE AND AIMS 
Multiplex assays can offer significant benefits for routine serological testing through reduced 
staff and reagent costs and streamlined laboratory operation (Pickering et al., 2002).  
xMap Luminex Technology allows the development of multiplex immunoassays where, multiple 
antibody types from a single serum, can be determined simultaneously in one assay run.  
Bexsero
TM
 vaccine against Neisseria meningitidis serogroup B has been approved in several 
countries. It is composed by three sub-capsular antigens, selected by reverse vaccinology 
approach: fHbp variant 1.1, NHBA peptide 2 and NadA variant 3. Bexsero
TM
 vaccine includes 
also Outer Membrane Vescicles (OMVs) derived from the New Zealand strain NZ98/254, 
expressing PorA serosubtype P1.4. However, it remains critical to evaluate whether circulating 
N. meningitidis strains express these antigens in order to predict the vaccine coverage 
(Boccadifuoco et al, 2012).  
The Meningococcal Antigen Typing System (MATS) was designed to measure immunologic 
cross-reactivity and quantity of vaccine antigens in target strains of N. meningitidis B. In 
particular, it is a combination of three sandwich Enzyme-Linked Immunosorbent Assay (ELISA) 
assays, one for each vaccine antigen, and the sequencing of PorA P1.4 (Serruto et al., 2012). 
However, a classical ELISA method could make multi-component vaccine immunogenicity 
evaluation difficult, laborious, time-consuming and expensive due to only one immunogen per 
assay run can be tested. 
Taking the case of MATS-ELISA assay and Bexsero
TM
 vaccine as reference, the PhD project 
aims are: (i) to develop a flexible multiplex and quantitative sandwich assay (on Luminex 
platform) allowing the simultaneous measurement of all vaccine antigens expressed by bacterial 
strains in order to predict the coverage of a multi-component based vaccine; (ii) to qualify the 
multiplex assay performances (reproducibility, sensitivity, accuracy, precision, intra/inter assay 
variability); (iii) to demonstrate the comparability of the new assay with previous data by using 
the relevant technical and statistical tools and bridge results with Serum Bactericidal Activity 
(SBA) of immune sera. 
 
 
 
 
  
9 
 
4. INTRODUCTION 
4.1 Vaccinology  
Along with improved sanitation and antibiotics’ discovery and use, vaccination is considered a 
fundamental milestone for healthcare, providing life-long protection against a wide variety of 
infections. Vaccines also represent the most cost-effective method of improving health and 
saving lives (Levine and Lagos, 2004).  
In 1796 Edward Jenner, following the path opened by the ancients who had used the smallpox 
virus itself in the practice of variolation, demonstrated that it was possible to protect people 
against smallpox through inoculation with cowpox (Variolae Vaccinae, from the Latin word 
vacca, cow). Although Jenner’s discovery was crucial, in the early 1800s the work of Louis 
Pasteur (figure 1) on chicken cholera, opened the way to vaccine development in the laboratory 
and set up the basis of vaccinology era (Plotkin, 2003), leading to identification of 
microorganisms as causing agents of infectious diseases. In fact, by accidentally leaving a 
bacterial culture without nutrients, he observed the presence of microorganisms showing 
attenuated virulence and able to confer immunity against disease. The French microbiologist 
referred to these attenuated bacteria as “vaccines” in honour of Edward Jenner’s discovery.  
Since then, the principle of “isolate, inactivate and inject” the causative agent of disease 
proposed by Pasteur, led the 
vaccine development throughout 
the 20th century (Plotkin, 2009). 
This empirical strategy has been 
applied for most of the vaccines 
licensed to date, that can be 
classified into three categories: 
inactivated microorganisms, live-
attenuated agents and subunit 
based vaccines (composed by 
infectious agent purified portions; 
Figure 1. Louis Pasteur, founder of modern microbiology who 
discovered the principles of vaccination 
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Moylett and Hanson, 2003). 
The main targets of these conventional vaccines are microorganisms that have invariant antigens 
or whose related disease results in natural immunity to reinfection (antibody-mediated 
responses; Rappuoli, 2007).  
Moreover, the difficulty to cultivate some pathogens in laboratory and the lack of suitable 
animal models of infection, constitute other major limitations to vaccine development. However, 
vaccines development for many pathogens remains elusive, and there is a growing requirement 
for the fast development of effective vaccines for emerging diseases (Morens, Folkers, et al., 
2008).  
During the last three decades, the vaccine field has been transformed by new technologies, such 
as recombinant DNA and chemical conjugation of proteins to polysaccharides. More recently, 
new antigen-discovery, new design methods and investigation of vaccine responses have been 
applied, including structural biology and systems biology. (Rinaudo, Telford, et al., 2009). 
Genome-based technologies have enabled functionally blind selection of vaccine candidates, and 
have not only led to the discovery of novel protective antigens, but have also revealed new 
virulence factors of several pathogens. Consequently, the pathogenesis-to-vaccine paradigm has 
been reversed in several situations, and vaccine development frequently leads to a better 
understanding of pathogenesis, which has in turn led to novel approaches in studying not only 
the organism itself, but also the strategies for the design of more successful vaccines. The 
genome era, in fact, has revolutionized vaccinology with the first complete genome sequenced of 
Haemophilus influenza in 1995 (Fleischmann, Adams, et al., 1995). 
The combination of sequencing technology with bioinformatics tools have resulted in the 
concept of “reverse vaccinology” (Rappuoli, 2000). The basic idea behind this strategy is the 
complete screening of the entire pathogenic genome by using computational analysis in order to 
identify interesting genes, encoding potential vaccine targets. Among them, there are virulence 
factors identified through sequence similarity to known pathogenic proteins, secreted or 
membrane-associated proteins containing signal peptides or anchoring motifs, lipoproteins and 
integral membrane proteins that could be involved in the recognition and interaction with host 
structures. The selected interesting ORFs are expressed and purified in Escherichia coli 
heterologous system, and then they undergo the normal laboratory testing for immune response. 
Only the antigens that provide high level of protection in animal model are selected for further 
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characterization before entering in clinical trials (Rappuoli, 2001). Reverse vaccinology 
approach was successfully applied for the first time in the identification of vaccine candidates 
against Neisseria meningitidis serogroup B (MenB), leading to a vaccine named Bexsero
TM
 that 
has been approved for use in more than thirty countries, especially in Europe and Canada. 
MenB, the major cause of meningococcal disease in the developed world, is an optimal example 
for which the conventional vaccines approaches failed. The success of reverse vaccinology for 
meningococcus catalyzed a paradigm shift in vaccine development, and paved the way to a 
variety of other genome-based vaccine discovery projects such as Streptococcus agalactiae, 
Streptococcus pneumoniae, Chlamydia pneumoniae, Bacillus anthracis, Porphyromonas 
gingivalis, Mycobacterium tuberculosis, Helicobacter pylori and others (Chakravarti, Fiske, et 
al., 2000; Ross, Czajkowski, et al., 2001; Wizemann, Heinrichs, et al., 2001; Ariel, Zvi, et al., 
2002; Betts, 2002; Montigiani, Falugi, et al., 2002). 
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4.2 Neisseria meningitidis and current meningitis vaccines  
N. meningitidis is a major cause of meningitis and sepsis, two devastating diseases that can kill 
children and young adults within hours, despite the availability of effective antibiotics. 
Meningococcus is a human-specific Gram-negative bacterium adapted to colonize the upper 
nasopharynx and directly spread from host to host, without requiring a reservoir outside humans. 
Carriage rates are very variable among human population, depending on different factors such as 
age, concurrent respiratory tract infections and frequency of social contacts. In Europe and 
United States, point-prevalence carriage rates have been estimated to range from 10% to 35% in 
young adults (Claus, Maiden, et al., 2005; Stephens, 2007).  
In a small but significant number of infections, the bacterium overcomes the respiratory tract 
epithelium and reaches the bloodstream, causing septicemia. From the blood, meningococcus is 
also able to cross the blood-brain barrier and infect the meninges, causing meningitis. The ability 
to colonize and cause disease results from meningococcus specific  mechanisms  to evade the 
human immune system (Lo, Tang, et al., 2009).  
A capsule made up of complex polysaccharides surrounds all currently known disease-causing 
meningococci and, is one of the essential meningococcal attributes for pathogenesis. The 
capsular polysaccharide (CPS) inhibits bacterial adhesion by masking the action of 
meningococcal adhesins and is critical for bacterial survival in the blood (Schneider, et al., 
2007). N. meningitidis can be classified in 12 serogroups on the basis of CPS  chemical 
composition, but, more than 95% of total cases of invasive disease are caused by five major 
serogroups: A, B, C, Y and W135. The distribution of the serogroups varies globally. There are 
an estimated 1.2 million cases of meningococcal infection per year, with a death toll of almost 
135,000 worldwide. Serogroup B meningococci, which are generally absent in Sub-Saharan 
Africa, are the primary concern in industrialized countries; however, changes in serogroup 
circulation are unpredictable and can occur very quickly (Khatami, 2010). Taking into account 
all these observations, it is widely recognized that vaccines conferring broad protection against 
N. meningitidis are a priority for of global health.  
Vaccines against serogroups A, C, Y and W135 were developed in the 1960s by using purified 
CPS as antigen. Since then more effective, conjugated vaccines have been introduced, in which 
CPS components are conjugated to carrier proteins such as CRM197, a non-toxic mutant of the 
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diphtheria toxin (Costantino, Rappuoli, et al., 2011). The first conjugate vaccines targeting group 
C N. meningitidis, that were developed to control the ongoing hyperendemic level of disease in 
infants and children, showed immunogenicity and safety in all age groups studied. Following the 
success of MenC vaccines quadrivalent meningococcal conjugate vaccines, containing the 
polysaccharide from serogroups A, C, Y and W135 conjugated to a carrier protein, have been 
introduced. These vaccines offered the potential to broaden protection against meningococcal 
disease beyond that offered by monovalent MenC conjugate vaccines: MenACWY-CRM, has 
been shown to be immunogenic in all age groups, including infants (Snape, Perrett, et al., 2008).  
Development of a broadly protective vaccine against MenB has been a difficult and unmet 
challenge for decades. The principal reason is that the MenB capsular polysaccharide, a 
homopolymer of α(2-8)-linked polysialic acid, is poorly immunogenic as it is antigenically 
similar to the human foetal neural cell adhesion molecule. This led to the concern that a MenB 
polysaccharide or glycoconjugate vaccine might induce autoantibodies (Finne, Leinonen et al., 
1983). Therefore, the search for a vaccine focused on non-capsular target antigens and, over the 
last 40 years, great efforts have been directed towards the identification of meningococcus B 
antigens as the basis of a new vaccine. However, the high sequence variability of these proteins 
among different MenB strains represents a serious obstacle to production of a globally effective 
anti-MenB vaccine (Bai, et al., 2010; Sadarangani, et al., 2010; Tan, Carlone, et al., 2010).  
Until recently licensed vaccines against serogroup B disease made use of outer membrane 
vesicles (OMVs), produced by detergent extraction of the bacterial outer membrane.  A variety 
of ‘tailor-made’ MenB OMV vaccines have been developed and licensed to control regional 
epidemics that, on the contrary of endemic disease, tend to be caused by a single clone of N. 
meningitidis. OMVs were able to induce protective antibodies against the homologous strain (i.e. 
the strain causing the epidemic and used to prepare the OMVs) in all age groups, and have 
proved to be successful in controlling epidemic disease in the onset’s countries  (Holst, et al, 
2013). The main limitation of OMV vaccines is that they are strain-specific and do not provide 
protection against heterologous strains, due to high variability across different isolates of PorA, 
which is the major protective antigen of the OMV-based vaccines, and  the most abundant 
integral outer membrane protein. As a consequence, there were no effective licensed vaccines 
available for the prevention of MenB disease, which is responsible for one third of 
meningococcal disease in the USA, and up to 80% of cases in Europe. A second generation of 
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OMV vaccines has been developed in order to broaden strain coverage. Meningococcal strains 
expressing six different PorA variants have been genetically engineered in order to produce the 
hexavalent PorA OMV vaccines (Claassen, Meylis, et al., 1996). However, since the use of 
multivalent OMV vaccines does not promise a simple universal solution, alternative approaches 
based on surface-exposed proteins were sought. 
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Figure 2. Schematic representation of Bexsero
TM development by reverse vaccinology 
4.3 Discovery of MenB vaccine antigens by reverse vaccinology and 
development of Bexsero
TM
 vaccine 
The availability of whole genome sequences, in the genomic era, has radically changed the 
approach to vaccine development. The genome represents a virtual database of all protein 
antigens that the pathogen can express at any time, so that it is possible to identify potentially 
surface-exposed proteins in a reverse manner, starting from the genome rather than from cultures 
of the microorganism (Rappuoli, 2001). The concept of reverse vaccinology was first 
successfully used by Novartis Vaccines and Diagnostics (now Gsk Vaccines) to develop a novel 
MenB vaccine, by using the genome of MenB strain MC58 ( figure 2; Pizza, Scarlato, et al., 
2000; Giuliani, Adu-Bobie, et al., 2006).  
The sequence of MenB virulent strain MC58 was determined by the shotgun strategy, revealing 
over 2000 predicted proteins (Open reading Frames, ORFs) (Tettelin, Saunders, et al., 2000). All 
the bacterial encoded proteins were screened for their potential localization on the bacterial 
surface by using bioinformatics algorithms, in order to identify novel vaccine antigens. 
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Those ORFs predicted to be surface-exposed or secreted, were expressed in E. coli as 
recombinant proteins, purified and then, tested for their potential to induce bactericidal 
antibodies (Pizza, Scarlato, et al., 2000). 
Each purified recombinant protein was used to immunize mice and antibody response was 
analyzed by Western blot analysis, using both total cell extracts and purified outer membrane 
proteins to verify protein expression. Surface localization of target protein was confirmed by 
Enzyme-Linked Immunosorbent Assay (ELISA) and flow cytometry on intact, whole bacteria.  
Since the main protective response against N. meningitidis relies on bactericidal circulating 
antibodies, complement-mediated bactericidal activity, measured by serum bactericidal activity 
assay (SBA) using human complement, is the accepted correlated for in vivo protection, and has 
been adopted in clinical trials of meningococcal vaccines as the surrogate for protection 
(Borrow, Carlone, et al., 2006). SBA was used to evaluate the complement-mediated killing 
activity of the antibodies. Among the 91 proteins found to be positive in at least one of these 
assays, 28 were able to induce antibodies with bactericidal activity.  
The antigens selected by reverse vaccinology were prioritized based on their ability to induce 
broad protection (i.e. ability to kill a diverse collection of strains) as inferred by SBA, or the 
Figure 3. Schematic representation of MenB vaccine antigens (NHBA, fHbp and NadA) on bacterial surface 
with the different bacterial compartments depicted. NHBA and fHbp’s structures are derived from the Nuclear 
magnetic resonance (NMR) structural data available and reported as cartoon, while NadA is a model based on the 
structural homology with other protein members of the Oca family (Serruto et al., 2012) 
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ability of specific antibodies to confer passive protection in the infant rat or mouse models 
(Giuliani, Adu-Bobie et al., 2006). The proteins that met these prioritization criteria (see figure 3 
on the previous page) were selected and called Genome-derived Neisseria Antigens (GNA) 2132 
(Neisseria Heparin Binding Antigen, or NHBA), GNA1870 (factor H binding protein, or fHbp) 
and GNA1994 (Neisseria adhesin A, or NadA). 
Two additional antigens, GNA2091 and GNA1030, were also selected due to their capability to 
induce protective immunity in some assays. In order to facilitate large-scale manufacturing of 
the vaccine, four of the selected antigens were combined as two fusion proteins. Among the 
several protein-protein fusions generated, the best performing combinations in terms of 
production and immunogenicity were NHBA plus GNA1030, and GNA2091 with fHbp. NadA 
did not perform well when fused to other proteins, probably due to the disruption of its trimeric 
organization. These two fusion proteins were formulated with NadA to produce a novel 
recombinant MenB vaccine (rMenB). To fully assess whether the vaccine formulation developed 
was able to induce protection against a wide proportion of MenB strains, a large panel of clinical 
isolates representing as much as possible the diversity of the bacterial population was collected. 
Sera obtained by immunizing mice with the vaccine were tested in a bactericidal assay against a 
panel of 85 meningococcal strains. Preclinical characterization showed that the vaccine induced 
bactericidal antibodies against 78% of the strains (Giuliani, Adu-Bobie, et al., 2006).  
To investigate ways of increasing immunogenicity, rMenB was also formulated with OMVs in a 
novel vaccine named 4CMenB (4 Components against MenB vaccine, figure 4). OMVs were 
produced in N. meningitidis strain NZ98/254 (expressing PorA serosubtype P1.4). The addition 
of MenNZB component was driven by the positive results obtained with the OMV-based 
Figure 4. 4CMenB vaccine composition (Domnich et. al., 2015) 
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vaccine, which was shown to be safe and efficacious in the control of the clonal meningococcal 
serogroup B epidemic in New Zealand (Oster, Lennon, et al., 2005).  
The final vaccine formulation, which was submitted in December 2010 to the European 
Medicines Agency for a marketing authorisation, is composed by rMenB+OMVnz and has been 
assigned the trade name of Bexsero
TM
. Bexsero
TM
 was approved by the European Commission 
on January 2013 as a vaccine formulated with aluminum hydroxide, to be administered by 
intramuscular injection (Findlow, et al., 2010; Snape. et al., 2010).  
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4.4 Components of Bexsero
TM
 vaccine 
 
4.4.1 Factor H binding Protein (FHbp) 
Factor H binding protein (fHbp or GNA1870) is an ubiquitous menigococcal surface-exposed 
lipoprotein (Masignani, et al., 2003) that binds human factor H (fH), an inhibitor of the 
alternative complement pathway. Evasion of the human complement system is critical for 
meningococci ability to cause invasive disease.  
Three-dimensional (3D) structure of the 28-kDa fHbp has been determined by both Nuclear 
magnetic resonance (NMR) spectroscopy (Cantini, et al., 2009; Mascioni, et al., 2010), and X-
ray crystallography (Cendron, Veggi, et al., 2011). Both structures reveal that fHbp is composed 
of two domains: a N-terminal domain of 10 anti-parallel β-strands forming a highly curved anti-
parallel β-sheet (approximating a β-barrel) and a C-terminal domain that is a well-defined β-
barrel comprising 8 anti-parallel β-strands.  
FHbp can be classified into three genetic and immunogenic variants: fHbp var.1, 2 and 3 (figure 
5, Masignani, et al., 2003), which are not cross-protective, and can be further divided into sub-
variants 1.x, 2.x and 3.x. Sequence conservation within each variant ranges from 92% to 100%, 
while between the variants the conservation can be as low as 63%.  
This diversity has an important impact on the immunological properties of fHbp, since members 
of each variant induce a strong protective immune response against meningococcal strains 
carrying homologous alleles, but are ineffective against strains that express distantly related 
VARIANT 3 
VARIANT 1 
VARIANT 2 
Figure 5. Phylogenetic tree showing phylogenetic relations between variants 1 (orange circle), 2 (green circle) 
and 3 (light blue circle) of fHbp (Masignani, 2014) 
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variants (Masignani. et al., 2003). In a different nomenclature scheme based on genetic 
information, the variants have been grouped into family A (var.2 and var.3) and family B (var.1) 
(Fletcher, et al., 2004).  
4.4.2 Neisseria adesin A (NadA) 
NadA (Neisseria adhesin A or GNA1994) is 38-kDa protein which belongs to the class of 
trimeric auto-transporter adhesins (TAAs) (Pizza, et al., 2000; Pillai, et al., 2005). TAAs mediate 
adhesion through interaction with extracellular matrix proteins, and are involved in invasion of 
target cells (Plested, et al., 2008). Structurally, they are obligate homotrimers, and accordingly 
the recombinant NadA-3 (the variant included in Bexsero
TM
 vaccine), lacking of the C-terminal 
membrane anchor region, forms soluble, stable trimers (Rosenqvist, et al., 1995). TAAs are 
generally formed by a conserved C-terminal integral membrane β-barrel, which anchors the 
proteins to the outer membrane, and an N-terminal “passenger” domain responsible for adhesion. 
The TAA passenger domain typically is made of a central α-helical domain (stalk) forming 
coiled-coil structures and a distinct N-terminal domain (head) that is mainly responsible for 
binding to host cellular receptors.  
Two main genetically distinct groups of NadA have been identified that share overall amino acid 
sequence identities of 45–50%. Group I includes the three most common variants (NadA-1, 
NadA-2, and NadA-3), which share ∼95% sequence identity and are immunologically cross-
reactive (Comanducci, et al., 2004). Group II includes three rarer variants, sharing ∼90% 
sequence identity (Bambini et al., 2014): NadA-4, primarily associated with carriage strains (48. 
Comanducci et al., 2004), NadA-5, mainly found in strains of clonal complex 213 (Lucidarme, 
et al., 2009; Bambini, et al., 2014), and NadA6. Vaccine variant NadA-3 is highly 
immunologically cross-reactive with NadA-1, NadA-2, and other NadA-3 subvariants but poorly 
cross-reactive with NadA-4 (Comanducci, et al., 2004).  
 
 
4.4.3 Neisseria Heparin Binding Antigen (NHBA) 
NHBA (Neisseria Heparin Binding Antigen, or GNA2132) is a 51-kDa surface-exposed 
lipoprotein, target of both meningococcal and human proteases, which binds to heparin in vitro 
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through an arginine-rich region (Serruto, et al., 2010). Upon binding heparin, which is often used 
as a surrogate for host polyanions in in vitro assays, unencapsulated bacteria showed increased 
survival in human serum (Serruto, et al., 2010). In vivo, NHBA binds glysoaminoglycans (such 
as heparan sulfate), which are present in mucosal secretions. In this context, NHBA contributes 
to the interaction of meningococcus with the host cells (Vacca, et. al., 2016). These data may 
point to a role for NHBA in protection of unencapsulated meningococci (as found in the 
nasopharynx) against complement. The interactions between heparin and the complement 
system are complex and involve several of its component proteins (Sahu and Pangburn, 1993), 
including complement inhibitors such as fH, C4b-binding protein and vitronectin. It is 
conceivable that the establishment of an NHBA-heparin complex on the meningococcus cell 
surface could recruit complement inhibitors, which in turn act to prevent complement activation.   
Analysis of gene sequences from genetically diverse serogroup B strains reveals the existence of 
more than 400 distinct variants, named ‘peptides’, for which each is assigned a numerical 
identifier. The NHBA variant included in Bexsero
TM
 is the one which contains the amino acid 
sequence of the peptide 2. 
 
 
4.4.4 Outer Membrane Vesicles (OMVs) 
Outer Membrane Vesicles (OMVs) are spherical bi‐layered membrane structures with a diameter 
in the range of 20–250 nm, that are pinched off from the outer membrane of Gram‐negative 
bacteria. In natural OMVs of Neisseria meningitidis, a total of 155 proteins were identified: 
outer membrane proteins (such as porines), lipopolysacchharide (LPS), opacity‐associated 
protein C (Opc), periplasmic constituents (van de Waterbeemda, et al., 2010), and some 
Bexsero
TM
 component as porine A (PorA), fHbp, NadA (van der Pol, et al., 2015).  
PorA protein was identified as the major protective antigen in OMVs, but is highly variable 
between the circulating serogroup B strains. The OMV component of Bexsero
TM
 contains the 
PorA protein of subtype P1.7-2,4. The PorA Variable Region 2 (VR2) P1.4 epitope is the major 
PorA target for the immune response elicited by Bexsero
TM
 vaccine (Martin, et al., 2006). There 
were 28 porA subtypes (VR1 and VR2 combinations) present among the isolates, 24 of which 
were identified in just one (17 subtypes), two (5 subtypes), or three (2 subtypes) isolates each. 
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The four major subtypes (representing 62% of the isolates in total) were P1.7-2,4 (20%), P1.22,9 
(18%), P1.22,14 (17%), and P1.19-1,15-11 (7%) (Lucidarme, et al., 2010). 
 
4.5 Serum Bactericidal Activity assay (SBA): the only correlate of protection 
The serum bactericidal assay with human complement (hSBA) is a universally accepted 
correlate of protection against meningococcal disease that quantifies the complement-mediated 
killing of bacteria by functional antibodies present in sera from vaccinees (Vogel et al., 2010). 
In general, an hSBA titer ≥ 1: 4 is considered to be a correlate of protection. Despite its strengths, 
hSBA has some shortcomings. First of all, hSBA is a labor-intensive technique and testing a 
large number of single circulating strains would produce logistical difficulties. In the other hand, 
it requires collecting considerable amounts of sera from immunized individuals, which would be 
ethically debatable, especially in pediatric studies. Furthermore, the standardization of hSBA 
across numerous strains and complement sources is also burdensome (Donnely, et al., 2010; 
Boccadifuoco et al., 2012). While hSBA is able to assess the effectiveness of a vaccine by 
measuring bactericidal antibody titers, it does not provide information on the contribution of 
each vaccine component. Indeed, the surface-exposed proteins fHbp, NHBA, and NadA display 
considerable sequence and expression variability, as well as different degrees of cross-reactivity 
among variants of a protein antigen to the antibodies induced by the vaccine (Beemink, et al., 
2009; Lucidarme, et al., 2010). For these reasons, an assay that can reliably assess the expression 
of those specific antigen variants, predicted to be targeted by bactericidal antibodies elicited by 
the vaccine on different bacterial isolates, is needed. 
 
 
 
 
 
  
23 
 
4.6 Meningococcal Antigen Typing System (MATS) 
To overcome the aforementioned limitations of SBA, a novel approach, named Meningococcal 
Antigen Typing System (MATS) has been developed. MATS, is an assay able to predict 
susceptibility of MenB isolates to vaccine-elicited bactericidal killing, measuring both antigenic 
reactivity and expression level of antigens on a given meningococcal strain (Donnelly, et al., 
2010).  
Basically, MATS combines 3 modified sandwich Enzyme-Linked Immunosorbent Assay 
(ELISA) assays, to measure antigenic cross-reactivity and expression of fHbp, NadA and NHBA 
on bacterial lysates, plus sequencing of dominant OMV immunogen. A strain that matches PorA 
serosubtype (PorA 1.4) is considered covered by Bexsero
TM
 vaccine. To evaluate whether the 
antigen content measured by MATS correlates with bactericidal activity, 57 serogroup B isolates, 
with known antigen genotypes and MATS values, have been tested by hSBA using pooled sera 
from infants immunized with 4CMenB vaccine. In details, MATS measures fHbp, NadA and 
NHBA content of serogroup B menigococcal (MenB) isolates relative to a reference strain in 
order to provide a “Relative Potency” (RP). By comparing MATS RP values with SBA results, 
threshold values were defined for each of the three antigens (Positive Bactericidal Thresholds, 
PBTs), specifically 2.1, 29.4 and 0.9% for fHbp, NHBA and NadA respectively. A strain with a 
relative potency above the PBT for at least one of the 3 antigens is predicted to be killed in SBA 
at a ≥ 80% probability (Donnelly, et al., 2010). 
Intrinsically, MATS is a conservative predictor since it leads to an underestimation of Men B 
coverage when compared to hSBA (Frosi, et al., 2013). 
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4.7 Principles of Luminex Technology: ELISA vs Luminex  
Immunogenicity is a crucial point of vaccine protective activity, and ELISA assay is the most 
common test to determine antibody titer against an immunogen. However, a classical ELISA 
method could make multi-component vaccine immunogenicity evaluation difficult, laborious, 
time-consuming and expensive due to only one immunogen per assay run can be tested. Another 
disadvantage is the assay limited dynamic range, such that repeated testing with further test 
sample dilutions may be necessary. In addition, ELISA is based on no covalent interactions of a 
molecule to a functionalized polystyrene plate (coating). As a consequence, the coating 
conditions setup could be difficult since it depends on many factors such as temperature, type of 
plate, immunogen chemical nature and concentration.  
Beside to the traditional ELISA approach, a possible alternative to test antibody response to a 
multi-component vaccine is represented by xMAP Luminex technology. This technology is 
mainly known for the possibility to manage multiple analytes within a single assay run.  
Due to robust multiplexing, xMAP technology potentially delivers more data in less time than 
other bioassay products, with comparable results to ELISA and microarray. The technology 
offers several other distinct advantages over traditional methods: a. speed/high-throughput (a 
large number of different bioassays can be performed and analyzed simultaneously thanks to the 
unique spectral signature of each beads); b. versatility (a single xMAP technology-based system 
can perform bioassays in several different formats); c. flexibility (the technology can be 
customized for the user’s specific needs or periodically updated by attaching a specific probe to 
a uniquely colored microsphere; d. accuracy (possibility to perform real-time analysis and 
accurate quantification of biological interactions); e. reproducibility (high-volume production of 
xMAP microspheres within a single lot allows a grade of assay standardization not provided by 
solid-phased planar arrays (Luminex corp website, last update 2016, 8th Sept)). 
Luminex approach relies on 6.2 µ diameter magnetic polystyrene microspheres (or beads), 
named MagPlex®, internally dyed with different intensities of red and infrared fluorophores. As 
a consequence, 100 distinct bead regions, based on dye mixture, have their unique spectral 
signature. Due to capacity of xMAP to uniquely detect and identify beads, simultaneous multiple 
measurements are possible (potentially up to 100 analytes/assay run).  
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Bead surface can be variously functionalized, e.g. carboxylated, allowing covalent coupling of 
analytes and bio-analytical reactions to take place over them. Inside the Luminex system, beads 
are lined up by fluidics in a single-line and pass through a detection chamber where a red laser 
excites their internal dyes allowing beads identification, and a green laser quantifies the bio-
molecular interaction occurring at bead surface. Software analysis sorts registered events by side 
scattering, thus events larger or smaller than a single microsphere are excluded, as well as 
aggregated microspheres (figure 6). 
 
 
Figure 6. Luminex technology: 100 distinct bead regions based on red/infrared dye mixture are available. 
Selected bead region is conjugated by COOH groups to NH2 of the analyte. Coupled beads react with the 
sample and bind detection Ab and a dye-labeled secondary Ab (e.g. sandwich assay). Sheath fluid aligns 
beads in single file through a cytometric flow. Assay results are expressed in Median Fluorescent Intensity, 
MFI 
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4.8 4-plex sandwich assay development on Luminex platform to predict the 
coverage of a protein-based vaccine: the BexseroTM example 
During my PhD, I have developed and qualified a flexible 4-plex sandwich assay on Luminex 
platform in order to predict the coverage of a multiple protein-based vaccine. In particular, I 
have focused my analyses on the coverage of Bexsero
TM
 vaccine versus circulating Men B strain.  
The first part of my work was devoted to selection of an optimal assay format, ending with two 
promising formats to be investigated: MATS-like format, which uses the same rabbit vaccine 
antigen-specific antibodies as capture and detection and NEW Format, where the capture Ab was 
substituted by a mouse vaccine Ag-specific Abs.   
The setup started on single-plex assay (one analyte/well). Both MATS-like and NEW format 
were investigated in order to study single-plex assay sensitivity and specificity by using 
recombinant vaccine antigens as a first step and, finally, testing Men B lysates. In detail, the 
performed steps were the following: a. identification of optimal capture and detection antibodies 
concentration to obtain a specific and linear signal with the best sensitivity and dynamic range; b. 
analysis of cross-reactivity between each vaccine Ags to obtain more information necessary to 
implement multiplex assay, c. investigation of assay reproducibility and d. matrix effect study. 
 Preliminary results on MATS-like format on Luminex platform have shown that, although 
different growing detection Ab concentrations were tested, it was no possible to reach the 
instrumental working range. This evidence has drawn attention to a possible risk to be not 
sensitive against heterologous Ag-expressing strains and has led to the selection of New Format 
as the best format candidate. The second part of my PhD project was focused on optimization of 
NEW Format assay by using Neisseria meningitidis serotype B as samples, in order to confirm 
reproducibility, specificity and sensitivity of single-plex format. In detail, I performed the 
analyses on a larger panel of MenB lysates normally used as quality control for MATS assay. 
This preliminary screening demonstrated that single-plex and multiplex assay show high 
correlation (R
2
>0.9 for each vaccine Ag between the two assays) and MFI profiles agree with 
antigen-expression and MATS data (data not shown). By using the software Softmax, I produced 
a relative potencies for MenB strains tested on multiplex assay, demonstrating that Luminex’s 
RPs are comparable with MATS’s RPs, since they are included in the 95% Confidence Interval 
of MATS’ RPs (data not shown). 
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Last part of my work was focused on qualification of optimized multiplex assay. In particular, I 
performed incubation times, specificity, sensitivity and reproducibility analyses, investigated 
precision of the assay and defined the assay cut-off following bioanalytical method validation 
guidance available in literature. Finally, I have screened a broad and heterogeneous panel of 28 
MenB lysates (a subset of the 57 tested to evaluate the performance of MATS (Donnelly et al., 
2010) and compared the results with SBA data. 
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5. MATERIALS AND METHODS 
 
5.1 Enzyme-Linked ImmunoSorbent Assay (ELISA) 
ELISA assay was used to assess immunogenicity of mouse and rabbit sera before the 
purification of  Bexsero
TM
 antigen specific IgG to be used for MATS and Luminex assay. 
 
5.1.1 ELISA equipment and softwares 
The following reagents and equipments are needed for the ELISA assay: Nunc Maxisorp  96-
well microtiter plates (Cod. 442404); saturation buffer 2.7% polyvinylpyrrolidone 15 (PVP)  in 
bi-distillated water; washing buffer for GNA2091-fHbp, NadA, NHBA-GNA1030 0.05% 
Tween20+PBS 0.074M (PBT), washing buffer for OMVs PBS 0.5X+Tween 20 0.05%; dilution 
buffer  1% BSA+0.05% Tween-20+PBS 0.074 M; alkaline phosphatase-conjugated secondary 
anti-species antibodies  (Sigma  Cod. A3687); substrate p-nitrophenyl phosphate (pNPP, Sigma 
cod. P7998); antigen dilution buffer 0,148 M (Na2HPO4 1,15 g, KCl 0,2 g, KH2PO4 0,2 g, NaCl 
8,0 g, pH  7,4  ±  0,1 in milliQ H20 filter-sterilized to 1 litre), 1.0 µg/ml of GNA2091-fHbp, 
NadA and NHBA-GNA1030 solutions, 5.0 µg/ml of OMVs solution, plate reader EPOCH, 
BioTek and plate washer BioTek ELx405. 
 
 
5.1.2 Experimental procedure  
ELISA for mouse sera 
96 well-plates are coated with 100 µl/well of 0.015 µM Bexsero
TM
 antigen solution and 
incubated overnight at 4°C (except for OMVs: plates are incubated 2.5 hours at 30°C). After the 
coating, plates are washed three times with washing buffer; 250 µl/well of saturation buffer is 
added and the plates are incubated for 2 hours at 37°C (1 hour at room temperature for OMVs). 
After 3-time washing with washing buffer, 1:40000 diluted mouse sera are dispensed (100 
µl/well) and diluted two-fold along the strips. Standard serum is represented by a pool of iper-
immune mouse sera and, as a positive control, a pool of medium/low immune responsive sera 
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was selected (both are dispensed at adequate dilution). Plates are then incubated for 2 hours at 
37°C, and wells are washed 3 times with PBT before addition of alkaline phosphatase-
conjugated secondary antibodies (100 µl/well, 1:2000 diluted). After 90-minutes incubation at 
37°C and 3-time washing with PBT, p-nitrophenyl phosphate is added (100 µl/well) and plates 
are incubated at room temperature for 30 minutes. Reaction is stopped by addition of of 4N 
NaOH (100µl/well) and OD 405/620-630 nm is measured. Antibody titers are expressed as 
ELISA units per millilitre (EU/ml o IU/ml) and are quantified via interpolation against a 
reference standard curve by using the software Combistats (version 4.0, EDQM). 
 
ELISA for rabbit sera 
The experimental procedure for rabbit sera follows the same steps and needs the same reagents 
used for mouse sera. The only exception is represented by the dilution factors of rabbit sera and 
relative secondary antibodies, which are respectively 1:10000 and 1:5000. 
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5.2 Serum Bactericidal Activity (SBA) assay  
 
Serum bactericidal activity against N. meningitidis strains was evaluated by using pooled baby 
rabbit serum (CedarLane) as complement source. Serum bactericidal titers were defined as the 
serum dilution resulting in 50% decrease in CFU/ml after 60 min incubation of bacteria with 
reaction mixture, compared with control CFU/ml at time 0. Typically, bacteria incubated with 
the negative control antibody in the presence of complement showed a 150 to 200% increment in 
CFU/ml during the 60 min incubation. 
 
5.2.1 Equipment  
A specialized equipment is required to study the serum bactericidal activity against N. 
meningitidis: a biosafety level 2 safety cabinet to manipulate the pathogens, a spectrophotometer 
to measure bacterial culture OD600 and incubators allowing optimal growth conditions (+37°C 
and 5% CO2).  
For menigococcal growth, the following media are needed: chocolate round agar plates 
(Biomerieux # 43101, stored at 4˚C) for overnight culture; Mueller Hinton Broth 
(DIFCO#275730, Becton Dickson Cat. no. 0757, stored at room temperature) for liquid culture 
and 25% w/v glucose (Sigma Cat. no. G7528, or equivalent) in milliQ H20 (filter-sterilized) To 
perform the assay the following materials are required:  
N. meningitidis test strains (collected and stored at -80° C) in Mueller Hinton Broth plus 7% w/v 
Glycerol ; rabbit or mouse test sera (usually kept at 20/-80°  for storage, stored at 4°C during the 
analysis and no longer than 1 month); positive controls (either serum samples or monoclonal 
antibodies); baby rabbit complement (CedarLane); Dulbecco’s saline phosphate buffer pH 7.4 + 
1% BSA (Bovine Serum Albumin,  ) + 0,1% glucose (filter-sterilized, and stored at +4°C); 96-
well tissue culture U-bottom plates; Mueller Hinton agar square plates (stored at 4°C);  . 
Rabbit serum used as a source of complement, is stored at -80° C; once thawed, an aliquot is 
heat inactivated at 56°C for 30 min and used as a source of inactivated complement. 
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5.2.2 Assay protocol 
N.meningitidis strains are plated onto chocolate agar plates and grown overnight at 37°C in a 
humidified chamber (5% CO2). The day after, bacterial colonies are collected and inoculated 
into 7 ml of MHB containing 0.25% (v/v) glucose. Bacterial growth at 37°C 5% CO2 is followed 
for 1 hour, starting from an OD600 of 0.05. The optimal OD600 to be reached is 0.23-0.24 and, it 
usually takes 1,5-2 hours to reach the desired OD, depending on the single strain.  
The assay is performed on 96 well plates in a final volume of 50 µl/well (refer to fig. 7 for the 
assay layout). Dulbecco’s PBS containing 1% (w/v) BSA and 0.1% (w/v) glucose is added to 
each well: 25 µl columns 1 to 11; 20 μl column 12 . Serial 2 fold dilutions of test sera are 
prepared dispensing 25 μl of pre-diluted sample (a 1:8 pre-dilution  in assay buffer will result in 
a 1:16 dilution in the first well of assay plate) in column 1, passing 25 μl from column 1 through 
column10 and discarding the last 25 μl. 
The SBA assay format has two kind of internal controls, that are used to calculate the average of 
colonies at time zero (T0).  
Complement Dependent Control (CDC), 
Column 11 (25μl of buffer; 12,5μl of active 
complement; 12,5 μl of bacteria; no serum), 
represents bacterial killing due to complement 
alone, in the absence of antibodies. 
Complement Independent Control (CIC), 
Column 12 (5 μl of pre-diluted serum; 12,5 μl 
of heat-inactivated complement and 20 μl of 
buffer), accounts for killing due to serum alone 
in the presence of heat inactivated complement. 
The 50% count of T0 is the number of colonies 
considered to define the higher bactericidal 
serum dilution.  
Following bacteria preparation steps must be 
conducted in the Biosafety Level 3 laboratories. 
Bacterial culture is diluted 1/10000 by serial Figure 7. Plate layout 
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dilution and 12,5 µl of bacterial culture are added to each well. 12,5 µl/well of active 
complement (obtained by reconstitution of lyophilized baby rabbit complement in 1ml of ice 
cold water) is  then added in columns 1 to 11, according to plate template (see fig. 7 on the 
previous page)., Bacteria are plated out at T0 by pipetting up and down the well content 3 times 
and then placing 10 µl from 2-4 wells of controls column 11 (CDC)  and 12 (CIC)  to the top of 
a square MH agar plate. Tilting the plate allows bacterial inoculum to run down to the plate 
bottom in a straight line. This will cause streak lines to form, leading to single colonies growth, 
that will simplify colony counting. Subsequently test plate is closed by lid, parafilm sealed and 
incubated for 1h at 37°C 5% CO2 under soft orbital shaking. At t=60 min, the contents of each 
well is mixed by pipetting up and down 3 times, and then 7 µl of each well are spotted on square 
MH agar plates as previously described for controls. After tilting, plate is incubated overnight at 
37˚C , 5% CO2.The day after, colony forming units (CFU) generated by single spots within each 
of the seeded plates are counted and recorded. All wells are plated in duplicate and duplicate 
counts must be recorded.  
Bactericidal titer is defined as the reciprocal of serum dilution that gives a 50% CFU decrease 
after 60 min incubation in the reaction mixture, compared with the mean CFU number in the 
control reactions at t=0. T0 average of both controls (column 11, CDC, and column 12, CIC), 
must be between 30 and 100 CFU. Killing by serum alone in presence of inactivated 
complement (CIC), should be minimal. In the case of meningococcal SBA, these values have to 
be less than 30% of T0 for the experiment to be considered valid. 
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5.3 Meningococcal Antigen Typing System (MATS) 
 
5.3.1 Equipment and softwares 
To perform a MATS assay the following materials are required, all of them to be prepared 
following Grifols Diagnostic Solutions’s procedures:  
test and reference strains (collected and stored at -80°C); anti-fHbp, anti-NHBA-GNA1030 and 
anti-NadA coated 96 microwell plates (to be stored between 2°C and 8°C); anti-fHbp, anti-
NHBA and anti-NadA biotinylated antibodies (to be stored between 2°C and 8°C); HRP 
conjugated streptavidin (to be stored between 2°C and 8°C); substrate buffer, (to be stored 
between 2°C and 8°C); properly diluted recombinant antigens (storage: PBS 1X); 5% Empigen 
BB lysis buffer detergent (Sigma Cat. 30326, to be stored at room temperature), ; 20X wash 
buffer (phosphate buffered saline, to be stored at room temperature); chocolate agar plates 
(Biomerieux cat. No. 43101); dehydrated Mueller-Hinton Broth (MHB) (Beckton Dickinson 
DIFCO cat. No. 275730); 95-97% sulfuric acid (H2SO4, Sigma-Aldrich Cat. No. 84720 or 
equivalent); sample buffer preparation (MHB+1/11 5% Empigen BB lysis buffer detergent), 
OPD tablets (Sigma P8287).  
The lab equipment needed for MATS is the following: incubator for bacterial cell culture (set-
point: 5% CO2, 37°C, 95% RH); laminar flow workbench (or safety cabinet); water bath; 
Ultrospec 10 Classic spectrophotometer (Amersham Biosciences distributed by GE Healthcare, 
Product No.80- 2116-30); TECAN Power Washer 384 or equivalent plate washer; dry incubator 
for ELISA plates (Set-point: 37°C), Molecular Devices Spectramax 340PC384 (Molecular 
Devices) or equivalent microplate reader with SoftMax Pro Data Acquisition and Analysis 
Software. 
 
 
5.3.2 Assay protocol 
MATS assay (see figure 8 on page 35) starts with overnight (16 hours) bacterial growth on 
chocolate agar plates (37°C, 95% of relative humidity, and 5% of CO2). The day after, bacteria 
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are resuspended in MHB to OD600 0.4 and lysed with 5% Empigen BB detergent (final volume 
of 1:11). Lysates are then inactivated at 45°C for 1 hour in a water bath. 
Duplicate two-fold serial dilutions of bacterial lysates are incubated in three different ELISA 
microwell plates (100 μl/well), each coated with rabbit polyclonal antibodies against fHbp, 
NHBA, and NadA, respectively. Plates are incubated for 1 hour at 37°C and washed with PBS 
1X/0.05% Tween20, after which detection of bound antigen is performed by addition of   
biotynilated rabbit IgG (100 μl/well), specific for each vaccine antigen, and 1 hour incubation at 
37°C. Finally, plates are washed and incubated with streptavidin-horseradish peroxidase (100 
μl/well) for 30 min at 37°C, followed by 20 min at room temperature with ortho-phenylene 
diamine substrate (100 μl/well). The reaction is stopped by adding 50 μl/well of 4 N sulfuric acid 
solution and OD 492nm is read by an ELISA reader (Molecular Devices Spectramax 340PC384 
or equivalent manufactured by Molecular Devices with SoftMax Pro Data Acquisition and 
Analysis Software). 
MATS readout of single meningococcal strains is expressed as Relative Potency (RP) for fHbp, 
NHBA, and NadA; RPs are calculated comparing serial dilution curves of tested strains with 
those of reference strains, whose RPs have been assigned the arbitrary value of 1 (or 100%), by a 
variance-weighted regression method. Reference strains are H44/76 for fHbp, NGH38 for 
NHBA, and 5/99 for NadA. 
In order to determine RPs cut-off values able to predict strain susceptibility by hSBA, MATS 
RPs have been related to hSBA titers of 13-months-old children pooled sera, immunized with 
4CMenB at 2, 4, 6, and 12 months of age. On this basis, the Positive Bactericidal Threshold 
(PBT) has been defined for each vaccine antigen component as the MATS RP point estimate 
above which the majority of strains are killed in hSBA. PBT values are 0.021 (2.1%) for fHbp, 
0.294 (29.4%) for NHBA, and 0.009 (0.9%) for NadA respectively (Donnelly, et al, 2010). 
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Figure 8. Schematic representation of MATS method 
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5.4 Luminex assay  
 
Luminex Technology (Luminex Corp., Austin, TX) is based on microscopic magnetic 
polystyrene particles (microspheres, diameter 6.2 µm) exposing on the surface multiple carboxyl 
groups as sites for covalent ligand attachment, and internally labeled with two different 
fluorophores. Each microsphere is identified by a unique ratio of the two different dyes 
obtaining up to 100 different fluorescent profiles (figure 9). 
As soon as a microsphere passes through the 
reader, the flow cell is interrogated by two 
different lasers. When beads are excited by a 
635 nm laser, the internal fluorophores emit at a 
characteristic wavelength which uniquely 
identified the microsphere. Simultaneously, a 
523 nm laser quantifies the amount of analyte 
bound to the microsphere by detecting the PE-
labeled reporter molecule, usually conjugated to 
the detection antibody, resulting in a signal 
expressed as median fluorescence intensity 
(MFI). 
 
 
5.4.1 Equipment, reading instrument and software 
A Luminex 200 instrument (Luminex Corporation) was used for plate reading. Median 
fluorescence intensity (MFI) was evaluated by using Bio-Plex manager 6.0 software (Bio-Rad, 
Hercules, CA). 
The equipment required for Luminex analyses developed in this work is the following: 
MagPlex® COOH microspheres (one single region for each specific Ab or Ag to be coupled); 
MenB lysates to be tested and antibody/antigen to be coupled; assay/dilution buffer (PBS 1X); 
detection antibody specific for the target antigen (either unlabeled or biotin-labeled); R-
Phycoerythrin AffiniPure F(ab')₂ Fragment Goat Anti-Rabbit IgG (H+L) (Jackson Immuno 
Research; Cat. N. 111-116-144); R-Phycoerythrin AffiniPure F(ab')₂ Fragment Goat Anti-Mouse 
6.2 microns 
Bead set 26 
Bead set 21  
Figure 9.  Principle of Luminex Technology: the 
unique ratio of red and infrared dye allows to obtain 
up to 100 different bead regions. 
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IgG (H+L) (Jackson Immuno Research; Cat. N: 115-116-146); assay buffer (Mueller-Hinton 
Broth+5% Empigen BB detergent); storage buffer (also used as reading volume to reduce 
aggregation; PBS 1X, 0.5% BSA, 0.02% Tween20), beads dilution buffer (PBS 1X+ 0.02% 
Tween 20), Low Bind tubes (Eppendorf; Cat. N.022431081), streptavidin-R-phycoerythrin 
(SAPE, Moss SAPE-001G75, Life Technologies S-866 or equivalent). Sample and beads 
loading are performed in 96-well Multiscreen HTS filters Plates (Millipore, Bedford, MA). 
For coupling methods the following reagents are needed: 1-Ethyl-3-[3-dimethylaminopropyl] 
carbodiimide hydrochloride (EDC, Pierce cat. N. 77149), Sulfo-NHS (Pierce cat N.24510 or 
24520), activation buffer (0.1 M NaH2PO4 pH 6.2; Sigma Cat. N.S3139), coupling buffer (50 
mM N‐morpholinoethane sulfonate (MES) pH 5.0, Sigma M2933), distilled deionized water 
(ddH2O). 
Microspheres should be protected from prolonged exposure to light throughout all steps.  
Washes are assessed by using an automatized magnetic washer (HydroSpeed 96i, Tecan, 
Männerdorf, Switzerland). During incubation steps, plates are placed on a titer plate shaker. 
 
 
   
5.4.2 Coupling: equipment and manual/automated methods 
There are approximately 100 million carboxyl groups on each MagPlex® COOH microspheres. 
Antibodies/antigens  are coupled by  two-step carbodiimide procedure during which microsphere 
carboxyl groups are first activated with EDC reagent in the presence of Sulfo-NHS to form a 
sulfo-NHS-ester intermediate. The reactive intermediate is then replaced by reaction with the 
primary amine of the target molecule (antibody, or peptide) to form a covalent amide bond 
(figure 10). 
 
Figure 10. Schematic representation of coupling reaction 
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Manual coupling 
For sandwich assay, 5 μg of each purified mouse IgG anti-fHbp, anti-NadA, anti-NHBA-
GNA1030 and anti-OMVs were coupled to 4 different spectrally unique MagPlex® 
microspheres (Luminex Corporation, Austin, TX). For the indirect assay, beads were coupled 
with 20 ug of each recombinant antigen (fHbp, NadA, NHBA, OMVs). . 
Beads activation: after resuspension, 1.5 x 10
6
 of stock uncoupled microspheres are transferred 
to a 1.5 ml LowBind eppendorf tube, that is placed for 30 to 60 seconds into a magnetic 
separator to allow beads separation and supernatant removal. The tube is then removed from the 
magnetic separator and the microspheres are resuspended in 100 μl of ddH2O by vortex and 
sonication for approximately 20 seconds. After a second separation and supernatant removal, 
taking care not to disturb the microspheres, beads are resuspended in 80 μl of 100 mM 
Monobasic Sodium Phosphate, pH 6.2 by vortex and sonication for approximately 20 seconds. 
Without washing, 10 μl of 50 mg/ml Sulfo-NHS (diluted in dH20) are added to the microspheres 
and gently mixed by vortex, followed by addition of 10 μl of 50 mg/ml EDC (diluted in dH20) 
and mixing by vortex. Beads are then incubated for 20 minutes at room temperature with gentle 
mixing by vortex at 10 minute intervals and finally, positioned into magnetic separator for 30 to 
60 seconds allowing separation. After the removal of the supernatant, microspheres are 
resuspended in 250 μl of 50 mM MES, pH 5.0 by vortex and sonication for approximately 20 
seconds. After a second MES washing and separation step the activated and washed 
microspheres are resuspended in 100 μl of 50 mM MES, pH 5.0 by vortex and sonication for 
approximately 20 seconds. At this stage, the optimal amount of Ab/Ag is added to the 
resuspended microspheres and total volume is brought to 500 μl with 50 mM MES, pH 5.0 and 
the coupling reaction is incubated for 2 hours with mixing (by rotation) at room temperature. 
After removal of supernatant into magnetic separator coupled microspheres are resuspended in 
500 μl of PBS-TBN by vortex and sonication for approximately 20 seconds. Two washes with 1 
ml of PBS-TBN are performed. Removing the tube from the magnetic separator the coupled and 
washed microspheres are resuspended in 250-1000 μl of storage buffer (PBS-TBN-BSA) in 
order to saturate with BSA activated carboxylic group eventually not conjugate to beads 
surfaces. 
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Count is assessed by hemacytometer (total microspheres = count (1 corner of 4 x 4 section) x (1 
x 10
4
) x (dilution factor) x (resuspension volume in ml)). Coupled microspheres should be stored 
at 2-8°C in the dark.  
 
Automated coupling 
In order to optimize and standardize the coupling reaction an automated coupling method was 
used. The method was developed, and subsequently applied according to the steps described for 
manual coupling, by using an automated liquid handling workstation (Hamilton –Microlab 
STAR IVD). 
 
 
5.4.3 Coupling confirmation  
Proteins and antibodies are typically coupled in random orientation as they have many lysine 
groups available for coupling. Functional testing is also critical during assay development. Once 
antibodies have been coupled to xMAP® beads, assessment of coupling efficiency before 
proceeding to assay development is strongly recommended. For this purpose, coupled and 
opportunely diluted microspheres react with 2-fold dilutions of PE-labeled anti-species 
secondary antibody (starting from 1:200; phycobiliprotein final concentration: 2.5 μg/ml - 
determined by absorption = 82.0 at 566 nm for a 1% solution for only those R-PE molecules to 
which at least one molecule of active antibody is bound) for 30 minutes at room 
temperature/dark room on a plate shaker. After three washes with PBS 1X, reading buffer is 
added (PBS 1X-Tween20 0.02%-BSA 0.5%) and samples flow through the fluidics of a 
Luminex® instrument. Coupling is confirmed if the signal obtained is linear respect to the 
dilution step of the detection antibody. 
If beads are coupled with an antigen, coupling confirmation is obtained by an indirect assay, 
where an Ab raised against the antigen target reacts with coupled beads for 30 minutes on a plate 
shaker at room temperature/dark room. After 3 washes with PBS 1X, a PE-labeled anti-species 
antibody reacts with the immune-complex per 15 minutes on a plate shaker at room 
temperature/dark room. After the plate washing, the reading volume is added and samples MFI 
signals are recorded by the instrument. 
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5.4.4  Inhibition assay 
An inhibition assay was developed in order to add information about assay specificity. MenB 
lysates reference strains were incubated with detection rabbit Abs mix, both at fixed 
concentration, followed by addition of 2-fold serial dilutions of capture mouse Ab. 
Not inhibited signal obtained from Ag-detection rabbit was quantified by the 4-plex assay using 
a PE-labeled anti-rabbit secondary Ab. Assay specificity was assessed by complete signal 
inhibition respect to control sample (no inhibitor).  
 
 
5.4.5  Multiplex sandwich assay (4-plex)  
A capture sandwich 4-plex immunoassay 
was developed to predict the coverage of a 
multi-component based vaccine. Sandwich 
assay is used to detect an antigen (target) 
with the use of a capture antibody attached 
to the surface of a microsphere and a 
detection antibody bound to a secondary 
anti-species Ab that incorporates a 
fluorescent label (figure 11). 
After the selection of the appropriate mouse antibody-coupled microsphere sets, beads are 
resuspended by vortex and sonicated for approximately 20 seconds. This step should be 
performed under a biosafety level 2 safety cabinet because the samples are bacterial lysates. 100 
μl/well of samples are dispensed in duplicate and 2-fold serial diluted in assay buffer (50 
μl/well). Four different coupled-bead sets (pAb anti-fHbp, anti-NadA, anti-NHBA-GNA1030 
and anti-OMVs) mixed at 1:4 dilution, are added to the pre-diluted samples (10 μl/well). 
Positive control is represented by a mix of recombinant of fHbp, NadA, NHBA and OMVs (final 
Ags concentrations: 0.25 μg/ml) and is added to the plate in duplicate as a single data-point. 
Standards curve is represented by a 2-fold serial diluted curve of each reference strain (H44/76 
for fHbp, 5/99 for NadA, NGH38 for NHBA and NZ98/254 for OMVs). Samples and beads are 
incubated for one hour (see table 1 on the next page for template layout). Plates are then washed 
Figure 11. Schematic representation of sandwich assay 
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Table 1. Template layout of 4-plex assay 
piastra 1 1 2 3 4 5 6 7 8 9 10 11 12
A Ref 1 Ref 1 Ref 2 Ref 2 Ref 3 Ref 3 Ref 4 Ref 4 Ukn 1 Ukn 1 Ukn 2 Ukn 2
B Ref 1 Ref 1 Ref 2 Ref 2 Ref 3 Ref 3 Ref 4 Ref 4 Ukn 1 Ukn 1 Ukn 2 Ukn 2
C Ref 1 Ref 1 Ref 2 Ref 2 Ref 3 Ref 3 Ref 4 Ref 4 Ukn 1 Ukn 1 Ukn 2 Ukn 2
D Ref 1 Ref 1 Ref 2 Ref 2 Ref 3 Ref 3 Ref 4 Ref 4 Ukn 1 Ukn 1 Ukn 2 Ukn 2
E Ref 1 Ref 1 Ref 2 Ref 2 Ref 3 Ref 3 Ref 4 Ref 4 Ukn 1 Ukn 1 Ukn 2 Ukn 2
F Ref 1 Ref 1 Ref 2 Ref 2 Ref 3 Ref 3 Ref 4 Ref 4 Ukn 1 Ukn 1 Ukn 2 Ukn 2
G Ref 1 Ref 1 Ref 2 Ref 2 Ref 3 Ref 3 Ref 4 Ref 4 Ukn 1 Ukn 1 Ukn 2 Ukn 2
H Ref 1 Ref 1 Ref 2 Ref 2 Ref 3 Ref 3 Ref 4 Ref 4 B B C+ C+
and 50 μl of detection rabbit antibody mix are added to wells. The mix is composed by pAbs 
anti-fHbp, anti-NadA, anti-NHBA and anti-OMVs with the final concentration of 3 μg/ml, 2.7 
μg/ml, 18 μg/ml and 13 μg/ml, respectively. After an incubation of one hour and plate washing, 
50 μl/well of phycoerythrin-conjugated anti-rabbit secondary antibody (starting from 1:200; 
phycobiliprotein final concentration: 2.5 μg/ml - determined by absorption = 82.0 at 566 nm for a 1% 
solution for only those R-PE molecules to which at least one molecule of active antibody is bound) is 
added and incubated for 15 min. The resulting immune-complexes are washed and resuspended 
in 1X PBS to be analyzed on the Luminex LX-200 system.  
All reaction steps were carried out at room temperature, in the dark and under agitation motion 
using a horizontal shaker; after each incubation step, plates were washed in 1X PBS by an 
automatized magnetic washer HydroSpeed 96i (Tecan, Männerdorf, Switzerland).  
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5.5  Recombinant vaccine antigens 
Antigens coupled to the Luminex microspheres (Luminex Corp.) and used as analytes for 
preliminary Luminex analyses were obtained from private sources (Gsk Vaccine Biochemistry 
Unit). 
 
 
 
5.6  Rabbit and mouse sera  
To perform each immunoassay described in this work, sera positive for each Bexsero
TM
 antigen 
were obtained by rabbit/mouse immunization with each antigen separately. Only sera with 
optimal Ab-titers were selected and used for the IgG purification. 
Animal treatments were performed in compliance with Italian laws and approved by the 
institutional rewiew board (Animal Ethical Committee) of Gsk Vaccine, Siena, Italy.  
For mouse sera, female CD1 mice (6-8 weeks aged) were immunized three times with 
intraperitoneal injection with 20 µg of fHbp, NadA and NHBA-GNA1030 and 10 µg of OMVs 
adjuvanted with 600 µg of Alum. Second and third immunizations were performed 21 days and 
35 days after the first dose, respectively. Pre-immune, post 2 (14 days after second dose) and 
post 3 (14 days after third dose) bleeding were collected for each mouse. Individual and group –
pooled sera were used for total and functional Abs detection. 
For rabbit sera, female New Zealand rabbit (weight:2-2.5 kg) were immunized four times with 
subcutaneous injection with 50 µg of fHbp, NadA and NHBA-GNA1030 and 25 µg of OMVs 
adjuvanted with 1500 µg of Alum. Second, third and fourth immunizations were performed 21 
days, 35 days and 49 days after the first dose, respectively. Pre-immune, post 3 (14 days after 
third dose), post 4 (16 days after fourth dose) bleeding were collected for each rabbit. Individual 
and group –pooled sera were used for total and functional Abs detection (see the tables 2 and 3 
on the next page for immunization schemes nomenclature). 
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R
A
B
B
IT
 
A
b
s 
anti fHbp rab-pool 
anti NadA rab-pool 
anti NHBA rab-pool 
anti OMVs rab-pool 
 
 
 
 
 
 
  
M
O
U
S
E
 A
b
s 
anti fHbp mouse-pool 1 
 anti fHbp mouse-pool 2 
 anti NadA mouse-pool 1 
anti NadA mouse-pool 2 
anti GNA1030-NHBA mouse-pool 1 
anti GNA1030-NHBA mouse-pool 2 
anti OMVs mouse-pool  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Mouse immunization schemes nomenclature 
Table 2. Rabbit immunization schemes nomenclature 
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5.7 Selection of polyclonal detection and capture antibodies (sandwich 
immunoassay)  
   
The selection of rabbit (detection) and mouse (capture) antibodies was performed based on 
ELISA results and by indirect Luminex assay as reported in section 6.1 (‘Results’ chapter). Both 
rabbit and mouse sera selected show bactericidal activity (see in paragraph 6.2 – ‘Results’ 
chapter).  The total IgG fraction of iper-immune mouse and rabbit sera were purified by using 
Protein G HP SpinTrap and Protein A HP SpinTrap, respectively. Rabbit and mouse specific IgG 
were also obtained from private sources (Gsk Vaccine Biochemistry Unit) and, in this case, IgG 
were titred by indirect Luminex assay. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
45 
 
5.8 Serogroup B strains panel selection
 
To explore the relationship between Luminex MFI obtained with the qualified 4-plex assay, 
bactericidal titers and MATS ELISA relative potencies for each individual antigen, 28 serogroup 
B strains were selected (table 4). In particular, these 28 strains are included in a 57-strains panel 
selected in 2010 by Donnelly et al. to evaluate the performance of MATS (in turns, a subset of 
124-strains panel tested on hSBA by using pooled sera from 141 infants who had received three 
immunizations or three immunizations plus one booster of 4CMenB). 
Strain 
Isolate 
Year Country Serogroup Serotype ST 
PorA 
VR1 
PorA 
VR2 
fHbp 
variant 
fHbp 
sub-
variant 
NHBA 
peptide 
NadA 
variant 
NadA 
sub-
variant 
961-5945 1996 AUS B 2b 153 21 16 2 16 20 2 3 
5/99 1999 NOR B 2b 1349 5 2 2 23 20 2 3 
M01-
0240364 
2001 GBR B 2a 11 5 2 3 31 28 2 5 
H44/76 1976 NOR B 15 32 7 16 1 1 3 NA NA 
M01239 1994 USA B 14 437 23 14 3 28 1 NA NA 
NZ98/254 1998 NZL B 4 42 7-2 4 1 14 2 NA NA 
NGH38 1988 NOR B NT 36 
 
3 2 24 2 NA NA 
M03369 1997 USA B 10 1576 19 15 3 31 16 NA NA 
NM117 1998 GBR B 21 1195 
 
9 1 15 21 NA NA 
M01-
0240988 
2001 GBR B 1 213 22 14 3 30 10 5 12 
M10837 2003 USA B NA 409 18-1 34-2 2 19 2 NA NA 
M10994 2003 USA B NA 44 21 16 2 19 29 NA NA 
M11003 2003 USA B NA 5097 7-2 4 1 4 2 NA NA 
M11048 2003 USA B NA 60 5-1 2-2 1 13 24 NA NA 
M12425 2004 USA B NA 44 7-1 1 1 83 29 NA NA 
M12886 2004 USA B NA 6147 22-15 28-2 1 4 10 NA NA 
M12898 2004 USA B NA 457 5-1 2-2 2 16 143 NA NA 
M14459 2005 USA B NA 2048 22 9 1 180 19 NA NA 
M14882 2006 USA B NA 44 7-1 1 2 19 29 NA NA 
M15564 2006 USA B NA 32 7 16 1 1 5 1 NA 
M16019 2007 USA B NA 32 7 16 1 1 5 1 NA 
M16405 2007 USA B NA 136 7-2 13-1 2 218 10 NA NA 
M16686 2007 USA B NA 2487 7-1 1 1 13 29 NA NA 
M18483 2008 USA B NA 2808 7-2 4 1 12 222 NA NA 
M01-
240500 
2001 GBR B NT 269 7 4 1 15 21 NA NA 
M01-
240660 
2001 GBR B NT 1049 19 15 1 15 21 NA NA 
M01-
240200 
2001 GBR B NT 275 22 9 1 13 17 NA NA 
 
 
Table 4. 28-sergroup B panel selected to be tested on new 4-plex Luminex assay 
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6. RESULTS 
6.1 Immunochemical characterization of animal sera used for 
capture/detection steps 
In order to generate antibody tools for Luminex assay, groups of rabbits (n= 3-15 /group) and 
mice (n= 8/group) were immunized with recombinant NadA, fHbp, NHBA and OMVs single 
antigens adsorbed to Alum Hydroxide as described in section 5.6 (‘Materials and Methods’ 
chapter). Two weeks after the third injection, antisera were collected and individually analyzed 
by ELISA or Luminex indirect assay to evaluate the level of antibodies induced by each 
Bexsero
TM
 vaccine component.  
 
 
6.1.1 Rabbit Sera 
All individual sera from each immunization group were able to elicit high antibody titers vs 
recombinant proteins and Outer Membrane Vesicles as well (panel 1).   
Upon ELISA titer evaluation antisera were also tested by SBA to assess presence of functional 
antibodies. 
Panel 1. Total IgG titers 
(GMT ± 95% CI) of 
rabbit sera raised against 
Bexsero
TM
 antigen 
components, as measured 
by ELISA on 
immobilized purified 
recombinant proteins 
NadA (A), NHBA (B) ,  
OMV (C) and fHbp (D), 
respectively 
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6.1.2 Mouse sera  
Mice antisera were collected two weeks after the third injection of individual Bexsero
TM
 
components, pooled and tested by Luminex for immunogenicity assessment. Anti OMVs mouse-
pool and anti fHbp mouse-pool 1 were titrated by 2-fold serial dilutions (starting point 1:5000) 
by using the indirect monoplex assay (beads only coupled with each corresponding vaccine Ag). 
Immuno-complexes were detected by a PE-labeled secondary anti-mouse Ab (starting from 
1:200 dilution, panels 2 and 3 - see on the next page).  
The same indirect assay was used for titration of purified IgG from anti NBHA-GNA1030 
mouse pool 1 and 2, anti fHbp mouse pool 1, anti NadA mouse pool 1 and 2, respectively. 
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Panel 2. Titration of mouse purified IgG by Luminex indirect assay. IgG anti NBHA-GNA1030 mouse 
pool1 and pool 2 titration started from 10 and 25 µg/ml of each purified Abs, respectively.  Anti NadA mouse 
pool 1 and pool 2 were titrated starting from 16 and 25 µg/ml, respectively  
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Panel 3. Titration of mouse purified IgG by Luminex indirect assay. anti fHbp mouse-pool 1 IgG were 
titrated starting from 10 µg/ml.  Titration started from a 1:5000 dilution for anti fHbp mouse-pool 2 and anti-
OMVs mouse-pool sera 
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6.2 Bactericidal activity assessment of selected rabbit and mouse sera 
The serum bactericidal assay (SBA) was used for antibody functionality evaluation.  
SBA measures the amount of serum antibodies required for bacterial killing by the classical 
pathway of complement activation. Since SBA titers are worldwide accepted as correlate of 
protection against N. meningitidis, they are the “gold standard” for evaluation of functional 
antibodies and, therefore, predominantly used during meningococcal vaccines development 
(Feavers and Walker, 2010).  
The preferred complement source for SBA is human serum. Alternatively, serum from different 
species (rabbit, rat) free of cross-reactive bactericidal antibodies can be used, since interfering 
endogenous antibodies to meningococcal antigens can be present in human sera due to a high 
frequency of meningococcal carriage among human population.  To ensure an adequate supply 
of complement commercially available sources are recommended (Giuliani, 2006) and, therefore, 
commercial rabbit complement was used in SBA for screening of antisera. 
SBA titers are defined as the reciprocal of the highest serum dilution at which 50% of bacterial 
killing is observed. 
 
 
 
6.2.1 SBA Analysis of rabbit sera 
Individual rabbit antisera raised against OMVs, NHBA NadA and fHbp were tested for the 
presence of bactericidal activity against the individual homologous N. meningiditis strains: 
NZ98/254 for OMVs, M4407 for NHBA, 5/99 for NadA and H44/76 for fHbp. As showed in 
figure 12 (see on the next page), all antisera tested showed protective antibody titers vs each 
homologous strain.  
Since the individual SBA titers measured were comparable within each immunization group, 
samples were pooled and rabbit IgG purified as described in section 5.7 (‘Materials and Methods’ 
chapter). 
Purified antibodies were used as detection reagents for the Luminex assay. 
 
 
  
50 
 
O M V N H B A N Ad A fH b p
1 0
1 0 0
1 0 0 0
1 0 0 0 0
1 0 0 0 0 0
S
B
A
 T
IT
E
R
(
F
o
ld
 I
n
c
r
e
a
s
e
)
S tr a in :        N Z 9 8 /2 5 4       M 4 4 0 7         5 /9 9          H 4 4 7 6
R a b b it   a n t i-
 
 
 
 
6.2.2 SBA Analysis of mouse sera 
Pooled murine antisera obtained from intraperitoneal immunization with OMVs, NHBA NadA 
and fHbp (as described in Section 5.6, ‘Materials and Methods’ chapter) were tested for the 
presence of bactericidal activity against the individual homologous N. meningiditis strains: 
NZ98/254 for OMVs, M4407 for NHBA, 5/99 for NadA and H44/76 for fHbp. SBA titers of 
pooled mouse sera are reported in table 5 (see on the next page). 
For fHbp, NadA and NHBA two mouse pools were tested by SBA, and their titers were very 
high and comparable for the same antigen.  A high SBA titer was also observed for the sera anti 
OMV mouse pool tested on a NZ98/254 homologous strain. 
IgG specific for each Bexsero
TM
 antigen component were purified from mouse pooled sera as 
described in section 5.7 (‘Materials and Methods’ chapter) and used as capture reagents for 
Luminex assay. 
 
 
Figure 12. rSBA titers vs antigen-homologous N. meningiditis strains. Individual titers are 
reported (dots) with the mean and SD. Titers are expressed as Fold Increase of post 3
rd
 dose 
serum vs pre-immune one 
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Table 5. rSBA titers of pooled mouse sera vs homologous N.meningiditis strains 
 
POOLED MOUSE SERA 
SERUM BACTERICIDAL TITERS 
AGAINST 
Specificity H44/76 M4407 5/99 NZ98/254 
Anti-fHbp pool 1 32768    
Anti-fHbp pool 2 65534    
Anti-NadA pool 1   8192  
Anti-NadA pool 2   16384  
Anti –NHBA pool 1  16384   
Anti-NHBA pool 2  65536   
Anti-OMVs pool    65536 
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6.3 Single-plex assay: design and optimization  
6.3.1 Coupling  
5μg of each vaccine Ag-specific mouse pAb (NEW format) and anti fHbp rab-pool (MATS 
format) was coupled to the carboxyl groups of 2.5 x 10
6
 MagPlex microspheres (Luminex 
Corporation, Austin, TX) following manufacturer's instructions. Each Ab was coupled to a 
microsphere set, identifiable through its unique spectral signature.  
Once antibodies have been coupled to the beads, coupling confirmation was assessed in order to 
achieve the best sandwich assay sensitivity and dynamic range. Antibody coupling is confirmed 
by testing the coupled microspheres with serial dilutions of a phycoerythrin (PE)-labeled anti-
species IgG antibody.   
A dose-response increase in terms of MFI should be observed over increasing concentration of 
anti-species Ab. In general, an antibody coupling should yield at least 10,000 MFI at saturation 
for optimal use in immunoassays. Results are reported in the following panels 4 and 5 (see on 
the next page). 
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Panel 4. Coupling efficiency assessment for beads coupled with anti fHbp mouse pool 1 and 2 and  anti NadA 
mouse pool 1 and 2 pAbs   
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6.3.2 Selection of sandwich assay format: comparison between Luminex MATS-like 
format and   NEW format for rfHbp antigen 
Following Luminex’s guidelines for multiplex assay development a Luminex single-plex 
sandwich immunoassay was initially developed as a first step, in order to identify the optimal 
capture and detection antibodies concentration to obtain a specific and linear signal with the best 
sensitivity and dynamic range. Each bead set was prepared following the procedure reported in 
the paragraphs 5.4.2 and 5.4.2 (‘Materials and Methods’ chapter). 
The first format tested on Luminex platform was the MATS-like (see fig. 13 on the next page, 
reference assay), characterized by the usage of same rabbit polyclonal antibody specific for the 
vaccine antigens both as capture and detection reagent; detection antibody is biotin-labeled and 
MFI signal is revealed by extravidin-PE. 
Sensitivity was the first parameter evaluated for single-plex. For this purpose, recombinant fHbp 
variant 1.1 (vaccine antigen variant) was used as analyte. Despite the high Ab concentration used 
(15 µg/ml of biotinylated anti fHbp rab-pool and starting from 1000 ng/ml of rfHbp 2-fold 
diluted - data not shown), MATS-like format achieved only half of the instrumental working 
range, and linearity was not as expected (five linear data-points: R
2
=0.71 - data not shown).  For 
this reason a different format, named NEW, was tested.  
NEW format microspheres are coupled with mouse polyclonal antibody (pAb) raised against 
rfHbp 1.1 (immunization schemes: anti-fHbp mouse-pool1 and pool2), while detection relies on 
the same anti-fHbp rab-pool pAb used for MATS-like format (see figure 14 on the following 
page). In this case, biotinylation of detection antibody was no necessary and MFI signal was 
detected by a PE-labeled anti-rabbit secondary Ab, a feature that may reduce the variability due 
to random biotinylation of detection Ab.  
Graph 1 (see on the next page) shows that NEW format achieved instrumental working range, 
obtaining optimal linear MFI signal (five linear data-points: R
2
=0.97), with lower detection 
antibody and recombinant antigen concentrations (1.5 μg/ml of not biotinylated anti-fHbp rab-
pool and starting from 15.6 ng/ml, respectively). This experiment demonstrates that changing 
species of capture antibody is possible to enhance the sensitivity of the assay, probably due to 
reduced competition between capture and detection Abs. In fact, when the same antibody is used 
as capture and detection, competition is generally increased in three-dimensional Luminex liquid 
kinetics assay compared to a traditional planar ELISA assay. 
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Figure 13. MATS-like format for Luminex assay 
 
Figure 14. New format for Luminex assay 
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Graph 2. MATS format on rfHbp 1.x sub-variants 
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Graph 3. New format on rfHbp 1.x sub-variants 
 6.3.3 Further investigation on selected formats:  sensitivity and specificity assay 
assessment on fHbp sub-variants  
Assay specificity was tested for both formats, in order to define which one was the best to be 
selected. Recombinant fHbp variant 1.4 and 1.15 were used as analytes.  
The aim was to understand if both formats were able to discriminate between two fHbp sub-
variants phylogenetically distant from the vaccine homologous one (for which capture/detection 
pAbs are specific).  
Also in this case, MATS-like format needed higher detection Ab concentration (15 μg/ml, graph 
2) to obtain specific and linear MFI signal compared to NEW format (we used 5 μg/ml in order 
to avoid not to detect the two sub-variants 1.x, graph 3). In both formats rfHbp variant 1.1 was 
better recognized than 1.4 and 1.15 (1.1>1.4>1.15) on Luminex single-plex assay, according to 
phylogenetic sequence distance and MATS data (Domnich et al. 2015), thus confirming 
preliminary specificity of the two formats.  
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6.3.4 Matrix interference study on binding Ag-Ab 
The next goal was to determine the matrix effect on binding between recombinant Ags and Abs 
on Luminex assay and instrumental fluidics. The sample to be used for the multiplex sandwich 
assay is a bacterial lysate, whose matrix is represented by Mueller Hinton broth + 5% Empigen 
Lysis Detergent. MATS format was tested using a detection anti-fHbp Ab concentration of 15 
μg/ml.  The two matrices tested were PBS 1X, usually used as matrix for Luminex assay, and 
MHB+LD (MATS assay matrix). As reported in the graph 4 on the next page, there is no 
significant different between the two matrices. Each experiment showed in the next pages was 
performed by using Mueller Hinton + Lysis Detergent as matrix. 
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6.3.5 Specificity investigation of fHbp-Luminex sandwich assay on MenB lysates 
Both formats were tested on a H44/76 lysate, the Men B strain used as fHbp reference in the 
MATS assay. The aim was to define the optimal anti-fHbp Ab concentration for detection of 
bacterial lysates, maintaining the linearity and sensitivity observed by using rfHbp as analyte. 
Each experiment was repeated 3 times (in duplicate) in order to calculate the standard deviation.  
As showed in graph 5 (see on the next page), MATS-like format noticeably lost assay sensitivity 
(i.e. at 1:32 dilution) and, it was not possible to enhance the MFI signal, even increasing the 
detection Ab concentration. On the other hand, NEW format preserved both assay sensitivity and 
linearity when applied to H44/76 strain lysate, also reducing detection Ab concentration (see 
graph 6 on the next page). To confirm this data, two additional Men B strains were selected: 
M16019, expressing the homologous vaccine variant of fHbp, (medium fHbp expression) and 
UK293, which expresses fHbp variant 2.19 (sub-variant not recognized by Bexsero
TM
-induced 
antibodies, Domnich, et al., 2010), as a negative control. 
Strains were tested by using the detection Ab concentration showing the best performance for 
each format (11 µg/ml for MATS-like format and 5 µg/ml for NEW format). In both formats 
(see graphs 7 and 8 on the next page), according to fHbp expression, detection Ab better 
recognized H44/76 var. 1.1 (reference strain) than M16019 (var. 1.1), while UK293 (var 2.19) 
strain was not recognized, as reported for MATS assay (Domnich et al., 2010), according with 
phylogenetic distance.  
In order to optimize the detection anti-fHbp Ab concentration for NEW format, an additional 
titration at 3 and 1.5 µg/ml was performed on the reference strain H44/76 (data not shown). 1.5 
µg/ml was selected as optimal concentration and was tested on additional strains to confirm that 
specificity was preserved (the experiment was repeated 3 times). According with phylogenetic 
distance (see figure 5 on page 19), strains expressing fHbp variant 1.x were recognized by 
detection Ab, while variant 2.x-expressing strains were not detected (see graph 9 on page 60). 
The optimal concentration of detection Ab for fHbp was set on 1.5 µg/ml, for NEW format, and 
11 µg/ml, for MATS-like format (not biotinylated and biotinylated anti fHbp rab-pool, 
respectively).  
MATS format (n=3) 
MATS format (n=3) –det Ab 11 µg/ml 
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6.3.6 Set-up of format conditions for NadA and NHBA  
Identification of optimal capture and detection antibody concentration to achieve the best 
sensitivity and dynamic range on both the MATS-like and New Format was performed for NadA 
and NHBA antigens.  
For both NadA and NHBA antigens, beads were coupled with anti-NadA mouse-pool 1 and anti 
NHBA mouse-pool 1 capture pAbs, respectively (according to paragraphs 5.4.2 and 5.4.3 of 
‘Matherials and Methods’ chapter). 
Detection NadA-specific rab-pool Ab was titrated at the concentration of 1.35, 0.8, 0.45 μg/ml 
by starting from 250 ng/ml of antigen (2-fold serial dilutions). The optimal detection Ab 
concentration was set to 1.35 μg/ml (see graph 10). 
 Detection NHBA-specific rab-pool Ab was titrated at the concentration of 4, 2, 1 μg/ml by 
starting from 2000 ng/ml of antigen (2-fold serial dilutions) and the optimal concentration of 
detection Ab was set to 4 µg/ml (see graph 11 on the next page).  
Testing the two selected concentrations on reference Men B lysates (5/99 for NadA and NGH38 
for NHBA), the optimal concentrations with best dynamic range were 1.35 μg/ml for anti NadA 
rab-pool Ab and 8 μg/ml for anti NHBA rab-pool Ab (data not shown). 
The results obtained on the MATS format were similar to those reported for rfHbp antigen: a 
higher concentration of detection Ab was needed for both NadA and NHBA antigens (data not 
shown), and this was no sufficient to reach the instrumental working range. 
 Thus, in order to avoid the risk of being not sensitive enough for heterologous variants, NEW 
format was selected as the best one for the 4-plex assay. 
 
 
 
 
 
 
 
Graph 10. NadA-specific rab-pool Ab titration on NEW format 
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6.3.7 Cross-reactivity study 
Cross-reactivity is defined as the ability of an antibody to react with similar antigenic sites on the 
surface of unrelated proteins, thus providing non-specific responses.  
The possible non-specific interactions were evaluated by using a 3-plex indirect assay for both 
mouse (capture) and rabbit (detection) Abs. 
Each Ab was tested starting from 4 μg/ml (2-fold serial dilutions) by using a mix of 3 different 
bead regions coupled with fHbp, NadA and NHBA, respectively.  
This analysis showed a weak non-specific interaction of anti-fHbp and anti-NHBA Abs with 
NHBA and fHbp, respectively (for both mouse and rabbit Abs, see panel 4 e 5 - on the next 
page). This evidence can be explained by a degree of sequence homology between the two 
antigens, due to their evolution from a common ancestor (Esposito et al., 2011). Anti NadA 
mouse-pool1 Ab showed a weak non-specific interaction with fHbp. This non-specific signal is 
detectable only at the highest Ab concentrations tested and so it is possible to avoid it increasing 
Abs dilutions. 
Graph 11. NHBA-specific rab-pool Ab titration on NEW format 
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MFI  
 
  
fHbp NadA NHBA  
 Ab anti fHbp rab-pool 27511.3 68.5 318  
 Ab anti NadA rab-pool 85.6 26962 56.5  
 Ab anti NHBA rab-pool 2005.6 341.5 24432  
 
  
MFI  
 
  
fHbp NadA NHBA  
 Ab anti fHbp mouse-pool 26024.5 127.5 1024.3  
 Ab anti NadA mouse-pool 726.5 28125.5 173.8  
 Ab anti NHBA mouse-pool 234.5 132 26839.3  
Panel 4. Cross-reactivity study on rabbit Abs by indirect assay 
 
Panel 5. Cross-reactivity study on mouse by indirect assay 
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6.3.8 Set-up of format conditions for OMVs  
 
Detection OMV-specific rab-pool Ab was titrated at the concentration of 3 and 1 μg/ml by 
starting from 15 μg/ml of antigen (2-fold serial dilutions) and the optimal concentration of 
detection Ab was set to 3 µg/ml (graph 12). However, testing the selected concentration on 
reference Men B lysate (NZ98/254 for NHBA), the optimal concentration with best dynamic 
range were 9 μg/ml (data not shown). 
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6.4 Incubation times 
Bexsero
TM
 Men B reference strains were used as analytes in order to optimize incubation times 
performance of the 4-plex assay.  
Sandwich assay protocol consists of three incubations: i) capture Ab-coupled beads/analyte 
reaction, ii) detection Ab binding to the analyte captured by coupled-beads and iii) recognition 
of detection Ab by a PE-labeled anti-species secondary Ab.  
 The following incubation time combinations were tested: A) i). 60 minutes;ii). 60 minutes; iii) 
15 minutes; B) i) 90 minutes; ii) 60 minutes; iii) 15 minutes; C) i) 60 minutes; ii) 90 minutes; iii) 
15 minutes; D) i) 90 minutes, ii) 90 minutes; iii) 15 minutes.  
The last incubation time was not changed since it involved a commercial secondary Ab used 
according to manufacturer’s instructions for optimal performance. Panel 6 and 7 (see on the next 
page) show that the combination A) could be considered the best one for fHbp antigen. 
Furthermore, there were no significant differences for NHBA and NadA antigens between the 
four combinations, while OMVs-MFI signals seemed to lose linearity with combination B), C), 
and D).  
Based on this observation, combination A) was selected, in order to save time and preserve assay 
linearity.  
  
Panel 6. Incubation time  study for fHbp  antigen 
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6.5 4-plex assay: correlation with single-plex 
Detection rabbit pAbs were titrated again when a new lot of mouse capture pAbs was used 
(immunization scheme anti fHbp mouse-pool1, anti NadA mouse-pool1, anti NHBA-GNA1030 
mouse-pool1, and anti OMVs mouse pool). Each reference and Quality Control (QC, see table 6 
on page 72) MATS strain was tested in order to bridge results obtained by using the old capture 
mouse pAb with the new one. Each experiment was repeated at least 3 times and the standard 
deviation was calculated. Panels 8, 9 (see on the following page) and 10 (see on page 69) show 
that there was no significant different between the two capture Ab lots. New detection rabbit 
pAb concentrations were set to 3 μg/ml for anti fHbp Ab, 2.7 μg/ml for anti NadA Ab, 18 μg/ml 
for anti NHBA and 13 μg/ml for anti OMVs Ab respectively. MFI signals detected showed the 
expected profiles for each strain, according to antigen-expression and MATS data (data not 
shown).  
Panel 8. Old vs new capture mouse pAb correlation on NEW format (reference strains) 
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Panel 9. Old vs new capture mouse pAb correlation on NEW format (QC MATS strains) 
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Panel 10. Old vs new capture mouse pAb correlation on NEW format (QC MATS strains) 
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Furthermore, single-plex and multiplex assay on reference and QC MATS strains have shown a 
good correlation with R
2
>0.9 for each vaccine Ag (panel 11 and 12 on the next page). 
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Panel 11. Single-plex vs 4-plex correlation for vaccine reference MenB strains. See details on Ag-
espression on the table 6 on page 72 
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Panel 12. Single-plex vs 4-plex correlation for MATS QC MenB strains. See details on Ag-espression on 
the table 6 on the next page 
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fHbp var./ subvar. 
NHBA 
peptide  
NadA var. 
PorA  
VR1-VR2  
 H44/76 1.1 (ref) 3 No gene P1.7,2.16 
5/99 2.23 20 3 (ref) P1.5-2.2 
NGH38 2.24 2 (ref) no gene P2.3 
NZ98/254 1.14 2 no gene P1.7-2,4 (ref) 
M11003 1.4 2 No gene P 1.7-2,4 
M11048 1.13 24 No gene P1.5-1,2.2-2 
961-5945 2.16 2 test P1.21,16 
M16019 1.1 5 1 P1.7,16 
M15564 1.1 5 1 P1.7, 2.16 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6. Summary of reference and MATS QC strains vaccine antigen expression 
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6.6 MATS assay vs 4-PLEX assay correlation  
Relative Potency (see section 5.3 of ‘Materials and Methods’ chapter for further information) 
values were calculated for MATS Quality Control and reference strains by using SoftMax 
ProData software for both assays and are reported in panel 13. Preliminary correlation results 
indicated that the 4-plex assay could be a promising candidate test to investigate coverage of 
Bexsero
TM
 vaccine.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Panel 13. Correlation MATS vs Luminex in terms of Relative Potencies. Data are expressed 
in average (n=3) for Luminex 4-plex assay and in geometric mean (n=18) for MATS assay.  
Luminex assay RP values were within the 95% Confidence Interval of MATS assay (data not 
shown). See details on Ag-expression on the table 6 on the previous page 
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6.7    4-plex sandwich qualification  
6.7.1 Specificity by inhibition assay  
To gain additional information on assay specificity an inhibition assay for our sandwich assay 
was developed. MenB lysates reference strains were incubated with detection rabbit Abs mix, 
both at fixed concentration, followed by addition of 2-fold serial dilutions of capture mouse Ab. 
Not inhibited signal obtained from Ag-detection rabbit was quantified by the 4-plex assay using 
a PE-labeled anti-rabbit secondary Ab. Assay specificity was assessed by complete signal 
inhibition respect to control sample (no inhibitor). These experiments confirm that each mouse 
antibodies used as inhibitor (the same coupled to the microspheres as capture) is appropriate and 
do not compete with lysate binding from rabbit detection antibodies. Only for NHBA we 
observed a competition that may be referable to the sequence homology between fHbp and 
NHBA. In fact, anti NHBA mouse-pool 1 could have bound a part of fHbp in the 4-plex assay, 
lightly enhancing fHbp inhibition and, consequently reducing NBHA inhibition. 
Inhibition percentage was calculated by using the following formula: 
100 − ( 
inhibited MFI signal
not inhibited MFI signal 
) ∗ 100 
Details on inhibition percentages and residual MFI signal for each Ag are reported on the table 7 
and graph 13, respectively. 
 
 
Ags 
Inhibition 
percentage 
(%) 
fHbp 93.7 
NadA 87.5 
NHBA 51.6 
OMVs 87.2 
Table 7. Inhibition percentage 
for each vaccine Ag 
Graph 13. Residual inhibition percentage for each vaccine Ag 
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6.7.2 Assay cut-off: LLOD and LLOQ  
The Lower Limit of Detection (LLOD) defines the smallest concentration of analyte that can be 
detected by an assay, with no guarantee about the bias or imprecision of the result.  
The LOD for 4-plex assay (see table 8 on the next page) was set at the highest point of dilution 
of Men B samples, with CV% intra-assay <15%, selected among the 28-panel strain tested and 
following the instructions below: 
-  for fHbp, variant 2 and 3 expressing strains that are not recognized by Bexsero
TM
 -induced 
Abs;  
-  for NadA, strains without NadA gene;  
- for NHBA, reference strain (because a NHBA-negative strain was not available within the 
panel tested); 
- for OMVs, hSBA negative strains.  
The Lower Limit of Quantification (LLOQ) is defined as the lowest concentration of analyte in a 
sample that can be consistently detected and quantitatively measured with suitable precision and 
accuracy (or linearity as surrogate of accuracy) under assay conditions. This corresponds to the 
quantifiable concentration threshold of the assay.  
The 4-plex assay LLOQ for each antigen was set at the highest value among the Lower Limit of 
Lineary (LLOL), the Lower Limit of Precision (LLOP) and the LLOD, which were calculated by 
considering 25 indipendent experiments conducted on each Bexsero
TM
 antigen reference strain, 
respectively (see table 8 on the following page). 
Contrary to the validation guidelines (LOD= blank samples average+3SD blank samples), LOD 
was calculated from not diluted negative samples. In fact, the assay matrix (MHB+LD) without 
strain component induced a background noise higher than the blank signal. This phenomenon 
may be explained by a possible saturating effect (like BSA) of bacterial lysate proteins that 
decreases the nonspecific binding in this immunoassay. 
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6.7.3 Precision: repeatability, CV% intra and inter-assay  
  
Repeatability of the assay was assessed for each antigen by determination of intra and inter-
assay variation. A set of 25 indipendent experiments with 4-plex assay performed in different 
days under the same operating conditions was used (table 9). 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 Ags LLOD  LLOQ 
A
n
ti
g
en
s 
fHbp 1064.8 1101.5 
NadA 1602.5 1602.5 
NHBA 3711.8 4189.4 
OMVs 5926.1 5926.1 
 
Ags 
CV% 
intra-assay 
CV% 
inter-assay 
fHbp 2,8 14,3 
NadA 2,3 10,44 
NHBA 4,02 24,4 
OMVs 3,3 12,6 
Table 8. LLOD and LLOQ of 4-plex assay expressed in terms of Median Fluorescent Intensity (MFI) 
Table 9. CV% intra and inter-assay of 4-plex assay 
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6.8 Screening of a broad and heterogeneous meningococcal B panel  
 
The 28-strain panel reported in the paragraph 5.8 (chapter 5. Materials and Methods) were tested 
on 4-plex optimized assay in order to investigate the correlation with MATS data. These 28 
strains are a sub-set of a 57-strain panel selected in 2010 by Donnelly et al. to correlate MATS 
results with hSBA.  
 
6.9 Statistical analyses  
 
We produced the Relative Potencies for each Men B strain tested by 4-plex assay in order to 
correlate 4-plex assay results with MATS data. For this purpose, we used a GSK validated 
spreadsheet which compares serial dilution curves of tested strains with those of reference 
strains, whose RPs have been assigned the arbitrary value of 1 (or 100%), by a variance-
weighted regression method. Each LLOQ was converted from Median Fluorescence Intensity in 
Relative Potency: 0.0001 for fHbp, 0.0816 for NHBA, 0.0009 for NadA and 0.0033 for OMVs. 
Statistical analysis on Luminex and MATS RPs dataset was performed by evaluation of correlation 
coefficient for each vaccine antigen by using Spearman method. The Spearman's rank-order 
correlation is the nonparametric version of the Pearson product-moment correlation. Spearman's 
correlation coefficient, (ρ) measures the strength and direction of association between two 
ranked variables.  
Spearman’s test showed that MATS RPs highly correlate with Luminex 4-plex assay RPs for 
NadA (ρ=0.99, spearman’s p value=0.0003, on the top of the panel 14, page 79) and, sensibility 
of 4-plex assay is the same of MATS assay on the 28-strain panel tested.  
We obtained a close correlation for NHBA as well (ρ=0.7, spearman’s p value=0.0002, on the 
bottom of the panel 14, page 79). However, five strains detected by MATS were just below the 
Luminex LLOQ. The calculation of NHBA LLOQ for Luminex, in fact, is highly conservative 
and underestimate the sensitivity of the assay. To optimized the LLOQ calculation for NHBA 
we need to test more NHBA expressing strains with low expression of this antigen.  
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The correlation for fHbp was weak (ρ=0.62, spearmna’s p value<0.05, top-graph in the panel 15, 
page 80) when we compared Luminex RPs with MATS RPs calculated for the MATS 
standardization in 2009. However, parameters for fHbp on MATS assay have been second time 
standardized on 2014 (data under publication) and, comparing Luminex RPs with the new 
calculated MATS RPs for this antigen, we observed a high correlation (ρ=0.85, spearman’s p 
value<0.0001, middle-graph in the panel 15, page 80). Moreover, 4-plex assay has a light higher 
sensitivity for fHbp, in fact it can detect one strain more respect to MATS assay (both 2009 and 
2014 standardizations). 
Looking at the RPs strain rank between the two assays, we observed that there is a high 
correlation for each antigen (see panels 17 and 18 on pages 82 and 83, respectively).  
In addition, we were able to obtain RPs values for OMVs (panel 16 on page 81). 4-plex assay 
measured, for the first time, the contribute of all OMVs components (not only PorA-correlated) 
in Bexsero
TM
 immune-response and, testing additional strains we may avoid MATS 
underestimation adding information on OMVs role in the vaccine coverage. 
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 Not Measurable Measurable 
Luminex 4-plex assay 22 6 
MATS-ELISA(2009) 22 6 
 Not Measurable Measurable 
Luminex 4-plex assay 5 23 
MATS-ELISA(2009) 0 28 
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Panel 14. Spearman’s test for correlation between MATS and Luminex for Nad A (top) and NHBA (bottom). X 
and y-axis report Luminex and MATS RPs for each antigen, respectively (log-scale). Dot-dashed lines are the 
LLOQ of both assays. Black dots represent the RPs of strains killed in hSBA. On the contrary, red dots are the RPs 
of strains not killed 
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Not Measurable Measurable 
Luminex 4-plex assay 12 16 
MATS-ELISA (2014) 13 15 
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Luminex 4-plex assay 12 16 
MATS-ELISA (2009) 13 15 
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Panel 15. Spearman’s test for correlation between Luminex 4-plex assay and both MATS-2014 (top, data under 
publication) and MATS 2009 (bottom) for fHbp. X and y-axis report Luminex and MATS RPs for each antigen, 
respectively (log-scale). Dot-dashed lines are the LLOQ of both assays. Black and red dots represent the RPs of 
strains killed not killed in hSBA, respectively 
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Not Measurable Measurable 
Luminex 4-plex assay 18 10 
MATS-ELISA (PorA genotype, 2009) 22 4 
OMV-PorA assays correlation 
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Men B strains 
Panel 16. Correlation between PorA genotype and Luminex RPs for OMVs. Light blue arrows represent the 
PorA P1.4 homologous strains and the dotted line is the Luminex OMVs LLOQ. Strains tested (from 1 to 28) 
and Luminex OMVs RPs are reported on x and y-axis, respectively. Black and red dots represent the RPs of 
strains killed not killed in hSBA, respectively 
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Panel 17. RPs strain rank comparison between the two assays for NadA and NHBA. Strains tested (from 1 to 
28) and Luminex RPs are reported on x and y-axis, respectively. Black and red dots represent the RPs of strains 
killed not killed in hSBA, respectively. Stars are MATS RPs and dots represent Luminex RPs. Dotted and dot-
dashed lines are the Luminex and MATS LLOQ, respectively 
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Panel 18. RPs strain rank comparison between the two assays for fHbp MATS RPs calculated in 2009 and 2014 
(data under publication). Strains tested (from 1 to 28) and Luminex RPs are reported on x and y-axis, respectively. 
In each graph, black and red dots represent the RPs of strains killed not killed in hSBA, respectively. Stars are 
MATS RPs and dots represent Luminex RPs. Dotted and dot-dashed lines are the Luminex and MATS LLOQ, 
respectively 
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7. DISCUSSION AND FUTURE PERSPECTIVES 
 
Invasive meningococcal disease (IMD) is caused by invasion of the bacterium Neisseria 
meningitidis into the blood stream and subsequent development of septic shock and purpura 
fulminans in a subset of patients. Meningitis is the consequence of bacterium access to the 
central nervous system. IMD is characterized by a death-rate of 5-15 % in developed countries, 
also in treated cases (Stephen and Pelton, 2016). 
The disease incidence is highest in infants and young children, with a second smaller peak in 
adolescents and young adults and varies by geographic region ranging from <.5 to .9 cases per 
100,000 population in North America and Europe to 10 to 1,000 cases per 100,000 population in 
the African meningitis belt (Stephen and Pelton, 2016). 
Bexsero
TM
 vaccine against serogroup B meningococci (4CMenB) was registered first in Europe 
in January 2013;  its composition is based on three  Neisseria recombinant  antigens, namely 
factor H binding protein (fHbp), Neisseria Heparin Binding Antigen (NHBA) and Neisseria 
adhesin A (NadA), combined with Outer Membrane Vesicles (OMVs) from MenB strain 
NZ98/254 containing porin A (PorA) serosubtype P1.4. 4CMenB vaccine components are 
present across most strains and are able to elicit bactericidal antibodies conferring protective 
immune responses (Pizza, et. al. 2000; Holst, et al. 2005, Wedege, et al. 2007).  
In contrast to homogeneous and highly conserved polysaccharides, surface proteins are 
heterogeneous and it complicates the development of protein-based meningococcal vaccines 
(Giuliani, et al. 2010). Effectiveness measurement of these vaccines is assessed by the Serum 
Bactericidal Assay (SBA), the only accepted correlate of protection against meningococcal 
disease, against many different strains for each geographic region. Actually, this approach is 
impractical, especially for infants, whose serum volumes are very limited.  
For this purpose, Meningococcal Antigen Typing System (MATS) was developed in 2010 
(Donnelly et al., 2010). MATS is a combination of three modified sandwich Enzyme-Linked 
Immunosorbent Assays (ELISA) that quantify on bacterial lysates  both protein content and level 
of matching with the corresponding antigen present in the vaccine (fHbp, NHBA, and NadA).  In 
addition, PorA serosubtype is identified by PCR genotyping by amplification of variable region 
2. 
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In 2013, it has been shown that MATS is a conservative predictor of Bexsero
TM
 strain coverage 
in infants and adolescents since, vaccine coverage results underestimated as per comparison of 
MATS prediction with hSBA titers (Frosi, et al. 2013). In addition, conventional ELISA makes 
immunogenicity evaluation of a multi-component vaccine laborious, time-consuming and 
expensive, since only one immunogen per assay run can be tested.  
In the last 20 years, microspheres-based multiplex immunoassays have been developed to 
identify infectious microorganisms and they represent a polyvalent approach which is able to 
unravel the complexity of bio-molecular interactions.  
The simultaneous measurement of multiple analytes (multi analyte profiling, xMAP) is attractive 
for many reasons. The possibility to test multiple analytes starting from the same sample leads to 
a considerable material saving, especially given that samples (e.g. sera) are often available in 
limited quantity. As consequence, samples volume, experimental times and workforce could be 
significantly decreased. Moreover, multi-analyte profiles can be obtained by combining relevant 
targets that are usually evaluated by separate methodologies (e.g. ELISA).  
Currently, multiplex assays based on microspheres are better applicable to traditional arrays 
(from 2 to 100 analytes) performed in liquid conditions, since they provide the best kinetic 
characteristics compared to ELISA planar arrays or glass chip. Multiplex liquid assays allow 
extremely fast interactions in high binding affinity reactions, and they can be easily modified by 
adding or removing microspheres population (one analyte=one microspheres set). In addition, 
laser detection is precise and consequently, Luminex Technology allows a good signal to noise 
ratio due to a minimum contribution of suspension buffer or sample matrix. 
For these reasons and, taking into account a possible modification of the current Bexsero
TM
 
formulation according to epidemiological needs, this work was focused on the possibility to 
switch from ELISA to the xMAP Luminex Technology in order to simultaneously quantify each 
vaccine antigen) and eliminate PorA sequencing adding information about whole (not only 
PorA-related) OMVs-contribute to Bexsero
TM
-induced immune response. 
The first attempt was based on transposition of the MATS Format, characterized by the same 
Ag-specific polyclonal rabbit Abs for both detection and capture steps, into the Luminex setting. 
Presumably, due to the liquid kinetics that amplifies the competition between the two Abs, no 
optimal signal, in terms of linearity and sensitivity, was observed.  
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Therefore, a different format (NEW Format), showing a better assay performance and based on 
usage of different species pAbs for capture and detection steps, was selected. 
A 4-plex sandwich immunoassay was set up, optimized and qualified by using the New Format, 
in order to predict the coverage of Bexsero
TM
 vaccine. The assay consists in a single multiplex 
sandwich test which simultaneously measures the four vaccine Ag content (fHbp, NadA, NHBA 
and OMVs) in Men B isolates. Vaccine Ags are captured from the bacterial lysates by mouse 
pAb-coupled beads and, the resulting complex, reacts with an Ag-specific rabbit pAb detected 
by a PE-labeled anti-rabbit Ab. 
For this purpose, 28 serogroup B strains were selected out of the 57-strains panel chosen by 
Donnelly et al. in 2010 to evaluate the performance of MATS (in turn a subset of a 124-strains 
panel tested by hSBA using pooled sera from 141 infants who had received either three 
Bexsero
TM
 immunizations or three immunizations plus one boost dose). This panel covers a wide 
range of responses for each of the three antigens and was tested at least twice, on different days, 
to evaluate assay performance (LLOQ, specificity, sensitivity, intra/inter-assay repeatability). 
For each vaccine antigen statistical analysis on Luminex and MATS RPs dataset was performed 
by evaluation of the Spearman’s correlation coefficient, demonstrating a statistically significant 
correlation between the Luminex 4-plex assay and MATS-ELISA relative potencies  (NadA: 
Spearman’s coefficient=0.99, p-value=0.0003; NHBA: Spearman’s coefficient=0.7, p-
value=0.0002; fHbp (2014): Spearman’s coefficient=0.85, p-value<0.0001; fHbp (2009): 
Spearman’s coefficient=0.62, p-value<0.05, see section 6.9 in the ‘Results’ chapter). As 
consequence, it is possible to speculate that Luminex 4-plex assay has a close correlation with 
the bactericidal titers as well. 
A critical factor that endorses a high added value to Luminex 4-plex assay compared to MATS, 
is the quantification, for the first time, of overall OMVs component (not only PorA-correlated) 
contribution to Bexsero
TM
-induced immune response. This demonstrates a major finding that 
may reduce the MATS underestimation. 
As far as the NHBA antigen is concerned, assay sensitivity resulted in underestimation since the 
LLOQ calculated for Luminex was quite conservative, probably due to the composition of the 
selected panel.  In fact, the original Donnelly’s 57-strains panel, from which our 28 strains were 
extracted, did not include a sufficient number of strains with low NHBA expression.  
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Before validation of Luminex 4-plex assay following the European immunoassay method 
validation’s guidelines (European Medicine Agency, 2011), optimization of sensitivity 
assessment for each antigen, by testing a statistically significant number of strains expressing 
different levels of vaccine Ags would be needed. 
Expanding the panel to be tested, it will be possible to evaluate the relationship between 
Luminex 4-plex assay and Bexsero
TM
 coverage by calculating the Positive Bactericidal 
Threshold (PBT: minimum amount of antigen needed for bacterial killing) for this new assay. 
A validated Luminex 4-plex assay would allow a fast and easy tracking of spatial and temporal 
changes in MenB epidemiology and their implications on 4CMenB coverage. Moreover, 
implementation of Bexsero
TM
 could potentially modify the population structure of N. 
meningitidis, increasing the proportion of strains not covered by the vaccine probably, thus 
requiring additional surveillance efforts.   
A possible implementation of the Luminex 4-plex assay would be testing whole inactivated 
bacterial samples, thus closer mimicking real conditions occurring in nature. 
Last, the Luminex 4-plex assay is highly flexible and easy to be modified for application to 
different targets, such as a second generation MenB vaccine or other N. meningitidis serogroups. 
In fact, since the genetic diversity of other serogroups is substantially lower compared to B one 
and, Bexsero
TM
 coverage on other serogroups carrying the vaccine antigens was demonstrated 
(Masignani, 2014), the establishment of a PBTs for each of them should be easily calculable.  
The analysis of non B serogroup meningococci by Luminex 4-plex assay will provide additional 
information on Bexsero
TM
 potentialities and possible resulting effects on N. meningitidis 
epidemiology. 
Moreover, reverse vaccinology has introduced the use of high-throughput technologies into 
vaccine research, affecting and improving vaccine antigen identification efficiency, development 
process, sample screening and vaccine coverage estimation (Donati and Rappuoli, 2013). 
Therefore, vaccine development based on reverse vaccinology could lead to the production of 
multi-component vaccines with broad protection and, immunoassays based on Luminex 
technology can be easily adapted in order to estimate the coverage of complex multi-component 
vaccines.  
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